WO2008031550A2 - Nicotinic acid derivatives as modulators of metabotropic glutanate receptors - Google Patents

Nicotinic acid derivatives as modulators of metabotropic glutanate receptors Download PDF

Info

Publication number
WO2008031550A2
WO2008031550A2 PCT/EP2007/007873 EP2007007873W WO2008031550A2 WO 2008031550 A2 WO2008031550 A2 WO 2008031550A2 EP 2007007873 W EP2007007873 W EP 2007007873W WO 2008031550 A2 WO2008031550 A2 WO 2008031550A2
Authority
WO
WIPO (PCT)
Prior art keywords
chloro
hydroxy
cyclohexyl
phenylethynyl
methyl
Prior art date
Application number
PCT/EP2007/007873
Other languages
French (fr)
Other versions
WO2008031550A3 (en
Inventor
Ralf Glatthar
Donald Johns
Daniel Umbricht
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to US12/440,284 priority Critical patent/US20100041641A1/en
Priority to EP07818088A priority patent/EP2069305A2/en
Priority to MX2009002684A priority patent/MX2009002684A/en
Priority to BRPI0716527-7A2A priority patent/BRPI0716527A2/en
Priority to AU2007296964A priority patent/AU2007296964B2/en
Priority to JP2009527065A priority patent/JP2010502664A/en
Priority to CA002663113A priority patent/CA2663113A1/en
Publication of WO2008031550A2 publication Critical patent/WO2008031550A2/en
Publication of WO2008031550A3 publication Critical patent/WO2008031550A3/en
Priority to US13/569,734 priority patent/US20120309742A1/en
Priority to US14/200,085 priority patent/US20140187600A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Definitions

  • the present invention relates to new pharmaceutical uses of compounds acting as modulators of metabotropic glutamate receptors ("mGluR modulators”), including antagonists of metabotropic glutamate receptors ("mGluR antagonists").
  • mGluR modulators compounds acting as modulators of metabotropic glutamate receptors
  • mGluR antagonists antagonists of metabotropic glutamate receptors
  • mGluR5 antagonists antagonists of metabotropic glutamate type-5 receptors
  • WO 2005/079802 discloses mGluR5 antagonists and their use as pharmaceuticals.
  • mGluR modulating activity in particular antagonistic activity
  • mGluR ⁇ modulators e.g. mGluR5 antagonists
  • a first aspect of the invention concerns the use of an mGluR modulator for the treatment, prevention and/or delay of progression of cognitive dysfunction.
  • a further aspect of the invention relates to a method for the treatment, prevention or delay of progression of cognitive dysfunction in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of an mGluR, e.g. mGluR5, modulator.
  • an mGluR e.g. mGluR5, modulator.
  • a further aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an mGluR, e.g. mGluR5, modulator for the treatment, prevention or delay of progression of cognitive dysfunction.
  • an mGluR e.g. mGluR5
  • modulator for the treatment, prevention or delay of progression of cognitive dysfunction.
  • a further aspect of the invention relates to the use of an mGluR, e.g. mGluR5, modulator for the manufacture of a medicament for the treatment, prevention or delay of progression of cognitive dysfunction.
  • the mGluR modulator may be an mGluR5 modulator.
  • the mGluR modulator is an mGluR, e.g. mGluR5, antagonist.
  • Alkyl represents a straight-chain or branched-chain alkyl group, preferably represents a straight-chain or branched-chain C 1-12 alkyl, particularly preferably represents a straight-chain or branched-chain C 1-6 alkyl; for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert- butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, with particular preference given to methyl, ethyl, n-propyl and iso-propyl.
  • Alkandiyl represents a straight-chain or branched-chain alkandiyl group bound by two different carbon atoms to the molecule, it preferably represents a straight-chain or branched- chain C 1-12 alkandiyl, particularly preferably represents a straight-chain or branched-chain C 1- 6 alkandiyl; for example, methandiyl (-CH 2 -), 1 ,2-ethanediyl (-CH 2 -CH 2 -), 1,1-ethanediyl ((- CH(CH 3 )-), 1 ,1-, 1 ,2-, 1 ,3-propanediyl and 1 ,1-, 1 ,2-, 1,3-, 1 ,4-butanediyl, with particular preference given to methandiyl, 1 ,1-ethanediyl, 1 ,2-ethanediyl, 1 ,3-propanediyl or 1 ,4-butan
  • alkyl part of "alkoxy”, “alkoxyalkyl”, “alkoxycarbonyl”, “alkoxycarbonylalkyl” and “halogenalkyl” shall have the same meaning as described in the above-mentioned definition of "alkyl”.
  • Alkenyl represents a straight-chain or branched-chain alkenyl group, preferably C 2-6 alkenyl, for example, vinyl, allyl, 1-propenyl, isopropenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, etc. and preferably represents C 2 ⁇ alkenyl.
  • Alkynyl represents a straight-chain or branched-chain alkynyl group, preferably C 2 - 6 alkynyl, for example, ethenyl, propargyl, 1-propynyl, isopropenyl, 1- (2- or 3) butynyl, 1- (2- or 3) pentenyl, 1- (2- or 3) hexenyl, etc. .preferably represents C 2 - 4 alkynyl and particularly preferably represents ethynyl.
  • Aryl represents an aromatic hydrocarbon group, preferably a C 6 -io aromatic hydrocarbon group; for example phenyl, naphthyl, especially phenyl.
  • Alkyl denotes an "aryl” bound to an “alkyl” (both as defined above) an represents, for example benzyl, ⁇ -methylbenzyl, 2-phenylethyl, ⁇ , ⁇ -dimethylbenzyl, especially benzyl.
  • Heterocycle represents a saturated, partly saturated or aromatic ring system containing at least one hetero atom.
  • heterocycles consist of 3 to 11 ring atoms of which 1-3 ring atoms are hetero atoms.
  • Heterocycles may be present as a single ring system or as bicyclic or tricyclic ring systems; preferably as single ring system or as benz-annelated ring system.
  • Bicyclic or tricyclic ring systems may be formed by annelation of two or more rings, by a bridging atom, e.g. oxygen, sulfur, nitrogen or by a bridging group, e.g. alkandiyl or alkenediyl.
  • heterocyclic moieties include pyrrole, pyrroline, pyrrolidine, pyrazole, pyrazoline, pyrazolidine, imidazole, imidazoline, imidazolidine, triazole, triazoline, triazolidine, tetrazole, furane, dihydrofurane, tetrahydrofurane, furazane (oxadiazole), dioxolane, thiophene, dihydrothiophene, tetrahydrothiophene, oxazole, oxazoline, oxazolidine, isoxazole, isoxazoline, isoxazolidine, thiazole, thiazoline, thiazlolidine, isothiazole, istothiazoline, isothiazolidine, thiadiazole, thiadiazoline, thiadiazolidine, pyridine, piperidine, pyridazine, pyrazine,
  • Hetero atoms are atoms other than carbon and hydrogen, preferably nitrogen (N), oxygen (O) or sulfur (S). - A -
  • Halogen represents fluoro, chloro, bromo or iodo, preferably represents fluoro, chloro or bromo and particularly preferably represents chloro.
  • Compounds of the invention may exist in free or acid addition salt form.
  • reference to “compounds of the invention” is to be understood as embracing the compounds in any form, for example free base or acid addition salt form. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds of the invention, such as picrates or perchlorates, are also included. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and are therefore preferred.
  • any discussion of methods or references to the active ingredients also includes pharmaceutically acceptable salts. If these active ingredients have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center.
  • the active ingredients having an acid group (for example COOH) can also form salts with bases.
  • the active ingredient or a pharmaceutically acceptable salt thereof may also be used in the form of a hydrate or may include other solvents used for crystallization. Examples of mGluR5 modulators, e.g. antagonists, and their manufacture are known, e.g. from WO 03/047581 and WO 2006/114262, both of which are incorporated herein by reference.
  • the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures or diastereomeric mixtures. All optical isomers and their mixtures, including racemic mixtures, are part of the present invention.
  • the mGluR modulator is a compound of the formula (I), for example as described in WP 2007/071358:
  • R 1 represents optionally substituted alkyl or optionally substituted benzyl
  • R 2 represents hydrogen (H), optionally substituted alkyl or optionally substituted benzyl; or
  • R 1 and R 2 form together with the nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
  • R 3 represents halogen, alkyl, alkoxy, alkylamino or dialkylamino
  • R 4 represents hydroxy (OH), halogen, alkyl or alkoxy
  • Q represents CH, CR 4 or N
  • V represents CH, CR 4 or N
  • W represents CH, CR 4 or N
  • X represents CH or N
  • Y represents CH, CR 3 or N
  • Z represents CH 2 , NH or O; and provided that Q, V and W are not N at the same time; in free base or acid addition salt form.
  • the mGluR modulator is a compound of the formula (II), wherein a compound of the formula (II) is a compound of formula (I) in which at least one of Q, V and W is N; in free base or acid addition salt form.
  • the mGluR modulator is a compound of the formula (III), wherein a compound of the formula (III) is a compound of formula (II) in which Y is CR 3 ; in free base or acid addition salt form.
  • a compound of the formula (III) is a compound of formula (II) in which Y is CR 3 ; in free base or acid addition salt form.
  • X preferably represents CH.
  • Y preferably represents CH or CR 3 , wherein R 3 preferably represents halogen, particular preferably chloro.
  • Z preferably represents NH.
  • R 3 preferably represents fluoro, chloro, C 1-4 alkyl, e.g. methyl.
  • R 3 particularly preferably represents chloro.
  • the hetero atoms being selected from the group consisting of N, O, S
  • R 1 and R 2 form together with the nitrogen atom to which they are attached form an unsubstituted, a single or twofold substituted heterocycle having 5 - 9 ring atoms and 1 - 3 hetero atoms; the hetero atoms being selected from the group consisting of N and O; the substituents being selected from the group consisting of halogen and C 1-4 alkyl.
  • R 1 and R 2 preferably form together with the nitrogen atom to which they are attached an unsubstituted, a single or twofold substituted heterocycle selected from the group consisting of
  • substituents being selected from the group consisting of fluoro, chloro, methyl, ethyl, propyl, butyl, trifluoromethyl, fluoropropyl and difluoropropyl.
  • R 1 and R 2 preferably represent, independently from each other, C 1 -C 4 alkyl or benzyl, optionally substituted by Ci-C 4 alkoxy or halogen.
  • radical definitions apply both to the end products of the formulae (I), (II) and (III) and also, correspondingly, to the starting materials or intermediates required in each case for the preparation.
  • These radical definitions can be combined with one another at will, i.e. including combinations between the given preferred ranges. Further, individual definitions may not apply.
  • R 4 represents Ci-C 4 alkyl, preferably methyl, and the other substituents have the meaning given in this specification; wherein R 4 represents halogen, preferably chloro, and the other substituents have the meaning given in this specification.
  • R 4 represents CrC 4 alkyl, preferably methyl, and the other substituents have the meaning given in this specification; wherein R 4 represents halogen, preferably chloro, and the other substituents have the meaning given in this specification.
  • the mGluR modulator is a compound of the formula (IV), for example as described in WO 03/047581 :
  • n 0 or 1
  • A hydroxy X is hydrogen and Y is hydrogen, or
  • A forms a single bond with X or with Y;
  • R 0 is hydrogen, (C 1-4 )alkyl, trifluoromethyl, halogen, cyano, nitro, -COOR 1 wherein R 1 is (C ⁇ Jalkyl Or-COR 2 wherein R 2 is hydrogen or (C ⁇ alkyl, and R is -COR 3 , -COOR 3 , -CONR 4 R 5 Or -SO 2 R 6 , wherein R 3 is (C 1-4 )alkyl, (C 3 .
  • R 4 and R 5 independently, are hydrogen or (C 3 - 7 )cycloalkyl or optionally substituted phenyl, R' is hydrogen or (C 1-4 )alkyl and R" is hydrogen or (C ⁇ alkyl, or R' and R" together form a group -CH 2 -(CH 2 ) m - wherein m is 0, 1 or 2, in which case one of n and m is different from 0, with the proviso that R 0 is different from hydrogen, trifluoromethyl and methoxy when n is 0,
  • A is hydroxy, X and Y are both hydrogen, R is COOEt and R' and R" together form a group -
  • Exemplary compounds of formula (IV) include:
  • the mGluR modulator is a compound of the formula (V), for exaple, as described in WO 2006/114262:
  • R 1 represents hydrogen or alkyl
  • R 2 represents an unsubstituted or substituted heterocycle
  • R 2 represents an unsubstituted or substituted aryl
  • R 3 represents alkyl or halogen
  • X represents a single bond or an alkandiyl-group, optionally interrupted by one or more oxygen atoms or carbonyl groups or carbonyloxy groups in free base or acid addition salt form.
  • Exemplary compounds of formula (V) include:
  • Furan-3-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • Furan-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • Furan-2-carboxylic acid [(IS ⁇ SJ-S- ⁇ -chloro-phenylethynyO-S-hydroxy-cyclohexyll-amide
  • Furan-3-carboxylic acid ((1 R,3R)-3-hydroxy-3-m-toiylethynyl-cyclohexyl)-amide Furan-3-carboxylic acid ((1 S,3S)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide Furan-3-carboxylic acid (( ⁇ )-(1 R.SRJ-S-hydroxy-S-m-tolylethynyl-cyclohexyO-amide Furan-2-carboxylic acid ((1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide Furan-2-carboxylic acid ((1 S,3S)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide Furan-2-carboxylic acid (( ⁇ )-(1 R.SRVS-hydroxy-S-m-tolylethynyl-cyclohe
  • Tetrahydro-pyran-4-carboxylic acid (( ⁇ )-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
  • Furan-3-carboxylic acid [(1 R.SRJ-S-CS-fluoro-phenylethynyO-S-hydroxy-cyclohexyll-amide
  • Furan-3-carboxylic acid [(1S,3S)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • Furan-2-carboxylic acid [(1R,3R)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • Furan-2-carboxylic acid [(1 S,3S)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • 3H-lmidazole-4-carboxylic acid [(+)-(1 R,3R)-3-(3-fluoro-phenylethynyl)-3-hydroxy- cyclohexyl]
  • the mGluR modulator is a compound of the formula (Vl)
  • R 1 represents hydrogen or alkyl
  • R 2 represents an unsubstituted or substituted heterocycle or R 2 represents an unsubstituted or substituted aryl; R 3 represents alkyl or halogen; in free base or acid addition salt form.
  • the mGluR modulator is a compound of the formula (VII):
  • R 1 represents hydrogen or alkyl
  • R 2 represents an unsubstituted or substituted heterocycle or R 2 represents an unsubstituted or substituted aryl;
  • R 3 represents alkyl or halogen
  • X represents a single bond or an alkandiyl-group, optionally interrupted by one ore more oxygen atoms or carbonyl groups or carbonyloxy groups
  • the invention provides a compound of formula (VIII)
  • R 1 represents hydrogen or alkyl
  • R 2 represents an unsubstituted or substituted heterocycle or R 2 represents an unsubstituted or substituted aryl;
  • R 3 represents alkyl or halogen
  • R 1 preferably represents hydrogen or C 1 ⁇ alkyl.
  • R 1 particularly preferably represents hydrogen.
  • R 3 preferably represents Fluoro, Chloro, C 1-4 alkyl.
  • R 3 particularly preferably represents chloro or methyl.
  • R 2 further preferably represents phenyl or substituted phenyl, the substituents being selected from the group consisting of Hydroxy, Amino, Halogen, Nitro, Cyano, C 1-4 Alkyl, C 1 . 4 Alkoxy, C 1 . 4 Alkoxyalkyl, C 1 ⁇ Alkoxycarbonyl, Ci -4 Alkoxycarbonylalkyl, Ci. 4 Halogenalkyl, C 6 -io Aryl, Halogen- C 6-10 Aryl, C 6-10 Aryloxy, C 6-I0 -A ⁇ l-C 1 ⁇ alkyl.
  • R 2 particularly preferably represents an unsubstituted, a single or twofold substituted heterocycle having 5 - 9 ring atoms and 1 - 3 hetero atoms; the hetero atoms being selected from the group consisting of N, O; the substituents being selected from the group consisting of Halogen, C 1 ⁇ Alkyl.
  • R 2 particularly preferably represents an unsubstituted, a single or twofold substituted phenyl, the substituents being selected from the group consisting of fluoro, chloro, hydroxy, methyl, methoxy, methoxycarbonyl, trifluormethoxy, amino, dimethylamino, methylthio, methylsulfonyl.
  • R 2 very particularly preferably represents an unsubstituted, a single or twofold substituted heterocycle selected from the group consisting of
  • R 2 further very particularly preferably represents a substituent selected from the group consisting of
  • X preferably represents C ⁇ alkandiyl, C ⁇ alkandiyl with an oxygen group at the end or C ⁇ alkandiyl with an carbonyl group at the end, C 1-6 alkandiyl with an carbonyloxy group at the end.
  • X particular preferably represents, methandiyl (-CH 2 -), 1 ,2-ethanediyl (-CH 2 -CH 2 -), 1,1- ethanediyl ((-CH(CH 3 )-), , methandiyloxy (-0-CH 2 -), 1 ,2-ethanediyloxy (-0-CH 2 -CH 2 -), 1 ,1-ethanediyloxy ((-0-CH(CH 3 )-), methandiylcarbonyl (-CO-CH 2 -), 1 ,2- ethanediylcarbonyl (-CO-CH 2 -CH 2 -), 1,1-ethanediylcarbonyl ((-CO-CH(CH 3 )-), methandiylcarbonyloxy (-C(O)O-CH 2 -), 1,2-ethanediylcarbonyloxy (-C(O)O-CH 2 -CH 2 -), 1 ,
  • the invention provides a compound of formula (IX)
  • R 1 and R 2 are as defined above.
  • the invention provides a compound of formula (IX) as defined above, wherein R 2 is as defined above and R 1 represents hydrogen.
  • Examples of compounds of formula (VII), (VIII) and (IX) include: Furan-3-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • Furan-3-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • Furan-2-carboxylic acid [(1 R.SRVS-P-chloro-phenylethynyO-S-hydroxy-cyclohexylJ-amide
  • Furan-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • Furan-3-carboxylic acid ((1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide
  • Furan-3-carboxylic acid ((1 S,3S)-3-hydroxy-3-m-tolylethynyl-cyclohexy!-amide
  • Furan-3-carboxylic acid (( ⁇ )-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide
  • Furan-2-carboxylic acid ((1 R.SRJ-S-hydroxy-S-m-tolylethynyl-cyclohexyO-amide
  • Tetrahydro-pyran-4-carboxylic acid (( ⁇ )-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
  • Furan-3-carboxylic acid [(1 R,3R)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • Furan-3-carboxylic acid [(1 S,3S)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • Furan-2-carboxylic acid [(1 R,3R)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • Furan-2-carboxylic acid [(1 S,3S)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
  • modulators include compounds of the formula (I) as defined in WO 2004/014881 and compounds of the formula (I) as defined in WO 2007/021575; the contents of these publications are incorporated herein by reference.
  • Compounds of the invention may exhibit a marked and selective modulating, especially antagonistic, action at human mGluRs, in particular mGluR ⁇ s.
  • This can be determined in vitro for example at recombinant human metabotropic glutamate receptors, especially PLC- coupled subtypes thereof such as mGluR5, using different procedures like, for example, measurement of the inhibition of the agonist induced elevation of intracellular Ca 2+ concentration in accordance with L. P. Daggett et al., Neuropharm. Vol. 34, pages 871-886 (1995), P. J. Flor et al., J. Neurochem. Vol.
  • Cognitive dysfunction include deficits and abnormalities in attention and vigilance, executive functions and memory (for instance working memory and episodic memory).
  • Other disorders relating to cognitive dysfunction include sleep related breathing disorders (SRBD), behavioural impairments, information processing deficits and age-related disorders.
  • SRBD sleep related breathing disorders
  • behavioural impairments information processing deficits and age-related disorders.
  • ADHD attention-deficit hyperactivity disorder
  • childhood ADHD childhood ADHD
  • adult ADHD excess daytime somnolence
  • sleep apnea shift-worker's sleep-wake cycle disruption
  • traumatic brain injury neurodegenerative disorders with associated memory and cognitive problems (such as Alzheimer's disease, Lewy body dementia, senile dementia, vascular dementia, Parkinson's disease), chronic fatigue syndrome, fatigue associated with sleep deprivation or prolonged wakefulness, age-related decline in memory and cognitive function (such as mild cognitive impairment), cognitive impairment associated with mood disorders (such as depression) and anxiety, schizophrenia and day time sleepiness associated with narcolepsy.
  • Treatment may comprise cognitive enhancement.
  • cognitive enhancement includes, but is not limited to, cognition enhancement, vigilance, counteracting effects of fatigue, enhancing alertness, attention, memory (working, episodic), learning ability, reaction time, cognitive performance enhancement, excess daytime somnolence, reversal of information processing deficits, improvement of disorganization, i.e. improving organizational skills/level of organizational ability.
  • the appropriate dosage will vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.01 to about 100 mg/kg body weight, preferably from about 0.1 to about 10 mg/kg body weight, e.g. 1 mg/kg. In larger mammals, for example humans, an indicated daily dosage is in the range from about 0.1 to about 1000 mg, preferably from about 1 to about 400 mg, most preferably from about 10 to about 100 mg of an mGluR, e.g. mGluR5, antagonist or other modulator conveniently administered, for example, in divided doses up to four times a day.
  • an mGluR e.g. mGluR5
  • antagonist or other modulator conveniently administered, for example, in divided doses up to four times a day.
  • an mGluR modulator e.g. an mGluR5 modulator, in particular an mGluR5 antagonist
  • an mGluR modulator may be administered as single active agent or in combination with other active agents, in any usual manner, e.g. orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injection solutions or suspensions.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an mGluR modulator (e.g. an mGluR5 modulator, in particular an mGluR5 antagonist) in association with at least one pharmaceutical carrier or diluent for use in the treatment of cognitive dysfunction.
  • an mGluR modulator e.g. an mGluR5 modulator, in particular an mGluR5 antagonist
  • Such compositions may be manufactured in conventional manner.
  • Unit dosage forms may contain, for example, from about 2.5 to about 25 mg of one or more mGluR modulator, e.g. mGluR5 antagonist or other modulator.
  • the usefulness of the compounds of the invention in the treatment of the above-mentioned disorders can be confirmed in a range of standard tests including those indicated below:
  • compositions for enteral such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (human beings and animals) that comprise an effective dose of the pharmacological active ingredient alone or together with a significant amount of a pharmaceutically acceptable carrier.
  • the dose of the active ingredient depends on the species of warm-blooded animal, body weight, age and individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
  • compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.
  • Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragees, tablets or capsules.
  • compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
  • System 1 System 1 : Performed on a Waters system equipped with a CTC Analytics HTS PAL autosampler, 515 pumps, and a 996 DAD detector operating at 210 nm.
  • Example 1.1 6-(4-Chloro-phenylamino)-N, N-diethyl-nicotinamide hydrochloride 6-Chloro-N,N-diethyl-nicotinamide (100 mg, 0.47 mmol) and 4-chloroaniline (184 mg, 1.41 mmol) are suspended in a mixture of glacial acetic acid (0.6 mL) and water (1.4 mL). The reaction mixture is heated in a sealed 3 mL-vial to 100 0 C over night. After reaching room temperature the reaction mixture is poured onto MTBE (30 mL) and extracted with 2M HCI (3x 5 mL).
  • the combined acidic extracts are made alkaline by addition of 2M NaOH (10 mL) extracted with MTBE (3x 15 mL).
  • the combined organic extracts are dried (Na 2 SO 4 ) and evaporated to dryness to.
  • the residue is purified by flash-chromatography. To the combined product containing fractions is added 4M HCI in dioxane (0.25 mL) followed by evaporation. The residue is triturated with ether, filtered off, washed with cold ether and vacuum dried at 45 0 C to give the title compound as colorless crystals (90 mg, 56%).
  • the starting material can be prepared as described hereafter: 6-Chloro-N,N-diethyl-nicotinamide
  • chloronicotinoyl chloride (4 g, 22 mmol) is suspended in DCM (40 ml_).
  • DCM dimethylethylcarbonate
  • the reaction flask is placed in an ice bath and a solution of diethylamine (2.31 ml_, 22 mmol) and triethylamine (3.90 ml_, 27.8 mmol) in DCM (40 ml_) is added within 45 min keeping the internal temperature below 5 0 C.
  • the ice bath is removed and the reaction mixture is stirred for further 30 min.
  • Example 1.12 rac-[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(3-methyl-piperidin- 1 -yl)- methanone
  • Example 1.14 [6-(4-Methoxy-phenylamino)-pvridin-3-vl]-(3-methyl-piperidin-1-vl)-methanone hydrochloride
  • Example 1.15 (3-Methyl-piperidin- 1 -yl)-(6-pher ⁇ ylamino-pyridin-3-yl)-methanone hydrochlo ⁇ de
  • Example 2.1 [6-(5-Chloro-pvridin-2-vlamino)-pvridin-3-vlJ-piperidin-1-vl-methanone A solution of palladium(ll) acetate (2 mg, 9 ⁇ mol) and BINAP (5.6 mg, 9 ⁇ mol) in dry and degassed toluene (1.5 mL) is stirred for 10 min under Ar.
  • Example 2.2 Azepan- 1 -yl-[6-(pyridin-3-ylamino)-pyridin-3-yl]-methanone
  • the starting material was prepared as described hereafter:
  • 3-Ethyl pyridine (5.0 g, 46.7 mmol) was hydrogenated in AcOH (100 mL) over PtO 2 (500 mg) under 4 bar for 4 hours. The mixture was filtered through a pad of celite and washed with AcOH. The solvent was removed in vacuo and the residue was dissolved into water. The solution was basified by addition with 40% NaOH solution. The aqueous phase was extracted with Et 2 O. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford 3-ethyl piperidine (4.4 g, 83%) as a clear yellow oil.
  • the starting material was prepared as described hereafter: i) 3-propyl pyridine
  • 3-propyl pyridine (300 mg, 2.48 mmol) was hydrogenated in AcOH (20 mL) over PtO 2 (50 mg) under 4 bar for 16 hours. The mixture was filtered through a pad of celite and washed with AcOH. The solvent was removed in vacuo and the residue was dissolved into water. The solution was basified by addition with 40% NaOH solution. The aqueous phase was extracted with Et 2 O. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford 3-propyl piperidine (300 mg, 95%) as a clear yellow oil.
  • Example 4.1 [6 ⁇ (6-Methyl-pvridin-3-ylamino)-pyridin-3-yl]-piperidin-1-vl-methanone To 6-(6-methyl-pyridin-3-ylamino)-nicotinic acid (210 mg, 0.92 mmol) is added thionyl chloride (2 mL). The colorless suspension is refluxed under argon for 20 min. After cooling the excess thionyl chloride is stripped off.
  • the starting material can be prepared as described hereafter: i) Methyl 6-(6-Methyl-pyridin-3-ylamino)-nicotinate
  • the starting material can be prepared as described hereafter:
  • the starting material was prepared as described hereafter:
  • 2-Ethyl-3-methylpyridine was prepared by Suzuki coupling of 2-bromo-3-methylpyridine and ethylboronic acid according to the procedure given in Tetrahedron Letters 2002, 43, 6987- 6990.
  • the desired product was obtained in 52% yield after purification on silica gel.
  • 2-Ethyl-3-methyl pyridine (1.75 g, 11.1 mmol) was hydrogenated in a mixture of MeOH (32 mL) and concentrated aqueous hydrochloric acid (1.2 mL) in the presence of Nishimura catalyst (180 mg) under atmospheric pressure for 22 hours.
  • the mixture was filtered through a pad of celite and washed with MeOH.
  • the solvent was removed in vacuo and the residue was dissolved in water.
  • the aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM.
  • the starting material was prepared as described hereafter:
  • 5-Methyl-2-propyl-pyridine was prepared by Suzuki coupling of 2-bromo-5-methylpyridine and propylboronic acid according to the procedure given in Tetrahedron Letters 2002, 43, 6987-6990.
  • the desired product was obtained in 24% yield after purification on silica gel.
  • 5-Methyl-2-propyl-pyridine (345 mg, 2.55 mmol) was hydrogenated in a mixture of MeOH (10 mL) and concentrated aqueous hydrochloric acid (0.29 mL) in the presence of Nishimura catalyst (50 mg) under atmospheric pressure for 40 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM.
  • the starting material was prepared as described hereafter:
  • the starting material was prepared as described hereafter:
  • 5-Fluoro-2-propyl pyridine (182 mg, 1.04 mmol) was hydrogenated in a mixture of MeOH (10 mL) and concentrated aqueous hydrochloric acid (0.13 mL) in the presence of Nishimura catalyst (50 mg) at 4 bar for 3.5 hours.
  • the mixture was filtered through a pad of celite and washed with MeOH.
  • the solvent was removed in vacuo and the residue was dissolved in water.
  • the aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM.
  • Example 4.63 [5-Chloro-6-(6-methvl-pvridin-3 ⁇ vlamino)-pvridin-3-vlJ-[2-(1.2-difluoro-propyl)- piperidin-1 -yl]-methanone and
  • Example 4.64 [5-Chloro-6-(6-methyl-pyridin-3-ylamino)- pyridin-3-yl]-[2-(2-fluoro-propyl)-piperidin-1-yl]-methanone
  • the starting material was prepared as described hereafter: i) 2-(1 ,2-Difluoro-propenyl)-pyridine
  • 2-(1,2-Difluoro-propenyl)-pyridine (820 mg, 4.28 mmol) was hydrogenated in a mixture of MeOH (25 ml_) and concentrated aqueous hydrochloric acid (0.46 ml_) in the presence of Nishimura catalyst (100 mg) at atmospheric pressure for 24 hours.
  • the mixture was filtered through a pad of celite and washed with MeOH.
  • the solvent was removed in vacuo and the residue was dissolved in water.
  • the aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM.
  • Example 5.1 Azepan-i-vl-f ⁇ -chloro- ⁇ -tf-chloro-phenylamino ⁇ -pyridin-S-yll-methanone To a solution of 5-Chloro-6-(4-chloro-phenylamino)-nicotinic acid (72 mg, 0.25 mmol) and DIPEA (67 ⁇ L, 0.38 mmol) in 1 ,2-dimethoxyethane (1.2 mL) is added HATU (97 mg, 0.25 mmol) in one portion. The reaction mixture is stirred for 30 min at RT. Then, hexamethylene imine (24 ⁇ L, 0.2 mmol) is injected and stirring is continued for further 6h.
  • reaction mixture is evaporated to dryness and the residue is purified by preparative HPLC (YMC Pack Pro C 18 5 ⁇ m, 150 x 30 mm; AcN-H 2 O-0.1% TFA gradient 10% -> 100% AcN; flow: 20 mL min "1 ).
  • the fractions containing the product are combined and acetonitrile is evaporated.
  • the remaining aqueous solution is made alkaline by addition of solid NaHCO 3 and extracted with ethyl acetate.
  • the starting material can be prepared as described hereafter:
  • Example 5.2 rac-[5-Chloro-6-(4-chloro-phenylamino)-pyridin-3-yl]-(3-methyl-piperidin-1 -yl)- methanone
  • Example 6.1 Azepan-1-vl-f6-(4-chloro-phenvlamino)-5-methoxv-pyridin-3-yll-methanone
  • azepan-i-yl ⁇ e-chloro-S-methoxy-pyridin-S-yO-methanone 198 mg, 0.70 mmol
  • 4-chloroaniiine 270 mg, 2.11 mmol
  • finely ground anhydrous K 2 CO 3 (491 mg, 3.52 mmol).
  • the starting material can be prepared as described hereafter: i) ⁇ -chloro- ⁇ -methoxynicotinic acid
  • Example 6.2 Azepan-1 -yl-[5-methoxy-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]- methanone]
  • Example 6.4 [ ⁇ -Methoxy- ⁇ -f ⁇ -methyl-pyridinS-ylaminoj-pyridin-S-ylJ-piperidin- 1 -yl- methanone
  • the starting material can be prepared as described hereafter:
  • Example 8.1 f6-(4-Chloro-phenvlamino)-Dvridazin-3-vll-piperidin-1-yl-methanone
  • ⁇ - ⁇ -Chloro-phenylaminoJ-pyridazine-S-carboxylic acid 50 mg, 0.2 mmol
  • DIPEA 53 ⁇ L, 0.3 mmol
  • HATU 76 mg, 0.2 mmol
  • the starting material can be prepared as described hereafter: ⁇ -f ⁇ Chloro-phenylaminoj-pyridazine-d-carboxylic acid
  • the starting material was prepared as described hereafter:
  • the starting material can be prepared as described in example 9.1. v) and iv) starting from 6- Chloro-5-fluoro-nicotinic acid methyl ester.
  • Example 10 Example of Biological Testing.
  • Example compounds of the present invention activity of the Example compounds of the present invention, non limiting to the other compounds of the invention but merely used by way of example, was examined by measurement of the inhibition of the glutamate induced elevation of intracellular Ca 2+ - concentration following similar methods than those described in L. P. Daggett et al., Neuropharm. Vol. 34, pages 871-886 (1995), P. J. Flor et al., J. Neurochem. Vol. 67, pages 58-63 (1996).
  • the table below represents percentages of inhibition of the glutamate induced elevation of intracellular Ca 2+ -concentration at a concentration of 10 ⁇ M.
  • mGluR modulatos e.g. mGluR anatagonists on cognition and cognitive disorders, as described herein may be conducted in the following way.
  • the compounds of the present invention are able to penetrate the brain and bind to mGluR receptors, in particular mGluR5 receptors.
  • mGluR receptors in particular mGluR5 receptors.
  • patients taking a compound, such as an mGluR modulators as described herein have shown an increase in cognition or the like.
  • Clinical testing of the compounds as mentioned herein may be conducted, for example, in one of the following study designs. The skilled person will of course realise that such studies are considered as guidelines and the certain aspects of the studies may be modified and redefined depending on the circumstance and environment, for example.
  • Clinical Design 1 Improvement Trials
  • a patient population, with a normal control is dosed once a day for a week or longer and cognition is tested.
  • the test is designed to allow for improvement, I.e. that there is a measurable parameter increase.
  • the patients are tested at the beginning and at the end of the dosage period and the results are compared and analysed.
  • a patient population with a cognitive deficit is dosed once a day for a week or longer and cognition is tested.
  • the test is designed to allow for improvement, I.e. that there is a measurable parameter increase.
  • the patients are tested at the beginning and at the end of the dosage period and the results are compared and analysed.
  • Conditions that artificially impair cognition are one way to test enhancement of cognition. Such conditions are, for example, sleep deprivation and pharmacological challenges.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.

Description

New Uses of metabotropic qlutamate receptors
The present invention relates to new pharmaceutical uses of compounds acting as modulators of metabotropic glutamate receptors ("mGluR modulators"), including antagonists of metabotropic glutamate receptors ("mGluR antagonists"). In particular, the present invention relates new uses of antagonists of metabotropic glutamate type-5 receptors ("mGluR5 antagonists").
WO 2005/079802, WO 2003/047581 , WO 2004/000316, WO 2005/044265, WO 2005/044266, WO 2005/044267, WO 2006/114262 and WO 2007/071358 disclose mGluR5 antagonists and their use as pharmaceuticals.
It has been surprisingly found that compounds having mGluR modulating activity, in particular antagonistic activity, may be used to treat cognitive dysfunction. In particular, it has been found that mGluRδ modulators, e.g. mGluR5 antagonists, may be used to treat cognitive dysfunction.
Accordingly, a first aspect of the invention concerns the use of an mGluR modulator for the treatment, prevention and/or delay of progression of cognitive dysfunction.
A further aspect of the invention relates to a method for the treatment, prevention or delay of progression of cognitive dysfunction in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of an mGluR, e.g. mGluR5, modulator.
A further aspect of the invention relates to a pharmaceutical composition comprising an mGluR, e.g. mGluR5, modulator for the treatment, prevention or delay of progression of cognitive dysfunction.
A further aspect of the invention relates to the use of an mGluR, e.g. mGluR5, modulator for the manufacture of a medicament for the treatment, prevention or delay of progression of cognitive dysfunction. The mGluR modulator may be an mGluR5 modulator. In certain embodiments, the mGluR modulator is an mGluR, e.g. mGluR5, antagonist.
In the present specification, the following definitions shall apply if no specific other definition is given:
"Alkyl" represents a straight-chain or branched-chain alkyl group, preferably represents a straight-chain or branched-chain C1-12 alkyl, particularly preferably represents a straight-chain or branched-chain C1-6 alkyl; for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert- butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, with particular preference given to methyl, ethyl, n-propyl and iso-propyl.
"Alkandiyl" represents a straight-chain or branched-chain alkandiyl group bound by two different carbon atoms to the molecule, it preferably represents a straight-chain or branched- chain C1-12 alkandiyl, particularly preferably represents a straight-chain or branched-chain C1- 6 alkandiyl; for example, methandiyl (-CH2-), 1 ,2-ethanediyl (-CH2-CH2-), 1,1-ethanediyl ((- CH(CH3)-), 1 ,1-, 1 ,2-, 1 ,3-propanediyl and 1 ,1-, 1 ,2-, 1,3-, 1 ,4-butanediyl, with particular preference given to methandiyl, 1 ,1-ethanediyl, 1 ,2-ethanediyl, 1 ,3-propanediyl or 1 ,4- butanediyl.
Each alkyl part of "alkoxy", "alkoxyalkyl", "alkoxycarbonyl", "alkoxycarbonylalkyl" and "halogenalkyl" shall have the same meaning as described in the above-mentioned definition of "alkyl".
"Alkenyl" represents a straight-chain or branched-chain alkenyl group, preferably C2-6 alkenyl, for example, vinyl, allyl, 1-propenyl, isopropenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, etc. and preferably represents C2^ alkenyl.
"Alkendiyl" represents a straight-chain or branched-chain alkendiyl group bound by two different carbon atoms to the molecule, it preferably represents a straight-chain or branched- chain C2* alkandiyl; for example, -CH=CH-, -CH=C(CH3)-, -CH=CH-CH2-, -C(CH3)=CH-CH2-, -CH=C(CHa)-CH2-, -CH=CH-C(CH3)H-, -CH=CH-CH=CH-, -C(CH3)=CH-CH=CH-, CH=C(CHa)-CH=CH-, with particular preference given to -CH=CH-CH2-, -CH=CH-CH=CH-. "Alkynyl" represents a straight-chain or branched-chain alkynyl group, preferably C2-6 alkynyl, for example, ethenyl, propargyl, 1-propynyl, isopropenyl, 1- (2- or 3) butynyl, 1- (2- or 3) pentenyl, 1- (2- or 3) hexenyl, etc. .preferably represents C2-4 alkynyl and particularly preferably represents ethynyl.
"Aryl" represents an aromatic hydrocarbon group, preferably a C6-io aromatic hydrocarbon group; for example phenyl, naphthyl, especially phenyl.
"Aralkyl" denotes an "aryl" bound to an "alkyl" (both as defined above) an represents, for example benzyl, α-methylbenzyl, 2-phenylethyl, α,α-dimethylbenzyl, especially benzyl.
"Heterocycle" represents a saturated, partly saturated or aromatic ring system containing at least one hetero atom. Preferably, heterocycles consist of 3 to 11 ring atoms of which 1-3 ring atoms are hetero atoms. Heterocycles may be present as a single ring system or as bicyclic or tricyclic ring systems; preferably as single ring system or as benz-annelated ring system. Bicyclic or tricyclic ring systems may be formed by annelation of two or more rings, by a bridging atom, e.g. oxygen, sulfur, nitrogen or by a bridging group, e.g. alkandiyl or alkenediyl. A heterocycle may be substituted by one or more substituents selected from the group consisting of oxo (=0), halogen, nitro, cyano, alkyl, alkandiyl, alkenediyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, halogenalkyl, aryl, aryloxy and arylalkyl. Examples of heterocyclic moieties include pyrrole, pyrroline, pyrrolidine, pyrazole, pyrazoline, pyrazolidine, imidazole, imidazoline, imidazolidine, triazole, triazoline, triazolidine, tetrazole, furane, dihydrofurane, tetrahydrofurane, furazane (oxadiazole), dioxolane, thiophene, dihydrothiophene, tetrahydrothiophene, oxazole, oxazoline, oxazolidine, isoxazole, isoxazoline, isoxazolidine, thiazole, thiazoline, thiazlolidine, isothiazole, istothiazoline, isothiazolidine, thiadiazole, thiadiazoline, thiadiazolidine, pyridine, piperidine, pyridazine, pyrazine, piperazine, triazine, pyrane, tetrahydropyrane, thiopyrane, tetrahydrothiopyrane, oxazine, thiazine, dioxine, morpholine, purine, pterine, and the corresponding benz- annelated heterocycles, e.g. indole, isoindole, cumarine, cumaronecinoline, isochinoline, cinnoline and the like.
"Hetero atoms" are atoms other than carbon and hydrogen, preferably nitrogen (N), oxygen (O) or sulfur (S). - A -
"Halogen" represents fluoro, chloro, bromo or iodo, preferably represents fluoro, chloro or bromo and particularly preferably represents chloro.
Various compounds having mGluR, in particular mGluR5, modulating activity are described herein. Where the specification refers to compounds, agents or active ingredients of the invention, this is generally taken to mean a compound having mGluR modulating activity unless specified otherwise.
Compounds of the invention may exist in free or acid addition salt form. In this specification, unless otherwise indicated, reference to "compounds of the invention" is to be understood as embracing the compounds in any form, for example free base or acid addition salt form. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds of the invention, such as picrates or perchlorates, are also included. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and are therefore preferred.
It will be understood that any discussion of methods or references to the active ingredients also includes pharmaceutically acceptable salts. If these active ingredients have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The active ingredients having an acid group (for example COOH) can also form salts with bases. The active ingredient or a pharmaceutically acceptable salt thereof may also be used in the form of a hydrate or may include other solvents used for crystallization. Examples of mGluR5 modulators, e.g. antagonists, and their manufacture are known, e.g. from WO 03/047581 and WO 2006/114262, both of which are incorporated herein by reference.
On account of the asymmetrical carbon atom(s) that may be present in the compounds of the invention and their salts, the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures or diastereomeric mixtures. All optical isomers and their mixtures, including racemic mixtures, are part of the present invention. In one embodiment, the mGluR modulator is a compound of the formula (I), for example as described in WP 2007/071358:
Figure imgf000006_0001
wherein
R1 represents optionally substituted alkyl or optionally substituted benzyl; and
R2 represents hydrogen (H), optionally substituted alkyl or optionally substituted benzyl; or
R1 and R2 form together with the nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
R3 represents halogen, alkyl, alkoxy, alkylamino or dialkylamino;
R4 represents hydroxy (OH), halogen, alkyl or alkoxy;
Q represents CH, CR4 or N;
V represents CH, CR4 or N; W represents CH, CR4 or N; X represents CH or N;
Y represents CH, CR3 or N;
Z represents CH2, NH or O; and provided that Q, V and W are not N at the same time; in free base or acid addition salt form.
In another embodiment, the mGluR modulator is a compound of the formula (II), wherein a compound of the formula (II) is a compound of formula (I) in which at least one of Q, V and W is N; in free base or acid addition salt form.
In yet a further embodiment, the mGluR modulator is a compound of the formula (III), wherein a compound of the formula (III) is a compound of formula (II) in which Y is CR3; in free base or acid addition salt form. Preferred substituents, preferred ranges of numerical values or preferred ranges of the radicals present in the formula (I), (II) and (III) and the corresponding intermediate compounds are defined below.
X preferably represents CH.
Y preferably represents CH or CR3, wherein R3 preferably represents halogen, particular preferably chloro.
Z preferably represents NH.
R3 preferably represents fluoro, chloro, C1-4 alkyl, e.g. methyl.
R3 particularly preferably represents chloro.
R1 and R2 preferably form together with the nitrogen atom to which they are attached an unsubstituted or substituted heterocycle having 3 - 11 ring atoms and 1 - 4 hetero atoms; the hetero atoms being selected from the group consisting of N, O, S, the substituents being selected from the group consisting of oxo (=O), hydroxy, halogen, amino, nitro, cyano, C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxyalkyl, C^4 alkoxycarbonyl, C1-4 alkoxycarbonylalkyl, C1-4 halogenalkyl, C6-10 aryl, halogen- C6-io aryl, C6-1O aryloxy and Ce^o-aryl-C^ alkyl.
R1 and R2 form together with the nitrogen atom to which they are attached form an unsubstituted, a single or twofold substituted heterocycle having 5 - 9 ring atoms and 1 - 3 hetero atoms; the hetero atoms being selected from the group consisting of N and O; the substituents being selected from the group consisting of halogen and C1-4 alkyl.
R1 and R2 preferably form together with the nitrogen atom to which they are attached an unsubstituted, a single or twofold substituted heterocycle selected from the group consisting of
Figure imgf000008_0001
and the substituents being selected from the group consisting of fluoro, chloro, methyl, ethyl, propyl, butyl, trifluoromethyl, fluoropropyl and difluoropropyl.
R1 and R2 preferably represent, independently from each other, C1-C4 alkyl or benzyl, optionally substituted by Ci-C4 alkoxy or halogen.
The above mentioned general or preferred radical definitions apply both to the end products of the formulae (I), (II) and (III) and also, correspondingly, to the starting materials or intermediates required in each case for the preparation. These radical definitions can be combined with one another at will, i.e. including combinations between the given preferred ranges. Further, individual definitions may not apply.
Preference according to the invention is given to compounds of the formulae (I), (II) and (III) which contain a combination of the meanings mentioned above as being preferred.
Particular preference according to the invention is given to compounds of the formulae (I), (II) and (III) which contain a combination of the meanings listed above as being particularly preferred. Very particular preference according to the invention is given to the compounds of the formula (I) which contain a combination of the meanings listed above as being very particularly preferred.
Preferred are those compounds of formulae (I), (II) and (III) wherein R2 represents an unsubstituted or substituted heterocycle.
Particular preferred are compounds of formulae (Ha to Me) as shown below:
Figure imgf000009_0001
wherein the substituents have the meaning given in this specification;
Figure imgf000009_0002
wherein the substituents have the meaning given in this specification;
wherein the substituents have the meaning given in this specification;
Figure imgf000009_0004
wherein R4 represents Ci-C4 alkyl, preferably methyl, and the other substituents have the meaning given in this specification;
Figure imgf000010_0001
wherein R4 represents halogen, preferably chloro, and the other substituents have the meaning given in this specification.
Further preferred compounds of the present invention have the formulae (Ilia to ille) as shown below:
Figure imgf000010_0002
wherein all of the substituents have the meaning given in this specification;
Figure imgf000010_0003
wherein the substituents have the meaning given in this specification;
Figure imgf000010_0004
wherein the substituents have the meaning given in this specification;
Figure imgf000010_0005
wherein R4 represents CrC4 alkyl, preferably methyl, and the other substituents have the meaning given in this specification;
Figure imgf000011_0001
wherein R4 represents halogen, preferably chloro, and the other substituents have the meaning given in this specification.
Particular compounds of the formulae (I), (II) and (III) include those described in the Examples given herein.
In another embodiment, the mGluR modulator is a compound of the formula (IV), for example as described in WO 03/047581 :
Figure imgf000011_0002
wherein m is 0 or 1 , n is 0 or 1 and A is hydroxy X is hydrogen and Y is hydrogen, or
A forms a single bond with X or with Y;
R0 is hydrogen, (C1-4)alkyl,
Figure imgf000011_0003
trifluoromethyl, halogen, cyano, nitro, -COOR1 wherein R1 is (C^Jalkyl Or-COR2 wherein R2 is hydrogen or (C^alkyl, and R is -COR3, -COOR3, -CONR4R5Or -SO2R6, wherein R3 is (C1-4)alkyl, (C3.7)cycloalkyl or optionally substituted phenyl, 2-pyridyl or 2-thienyl; R4 and R5, independently, are hydrogen or
Figure imgf000011_0004
(C3-7)cycloalkyl or optionally substituted phenyl, R' is hydrogen or (C1-4)alkyl and R" is hydrogen or (C^alkyl, or R' and R" together form a group -CH2-(CH2)m- wherein m is 0, 1 or 2, in which case one of n and m is different from 0, with the proviso that R0 is different from hydrogen, trifluoromethyl and methoxy when n is 0,
A is hydroxy, X and Y are both hydrogen, R is COOEt and R' and R" together form a group -
in free base or acid addition salt form.
Exemplary compounds of formula (IV) include:
(-HSaR^SJaRH-Hydroxy^-m-tolylethynyl-octahydro-indole-i -carboxylic acid methyl ester (-HSaR^SJaR^-Hydroxy^-m-tolylethynyl-octahydro-indole-i -carboxylic acid ethyl ester
(-)-(3aR,4S,7aR)-Furan-2-yl-(4-hydroxy-4-m-tolylethynyl-octahydro-indol-1-yl)-methanone
(±)- (3aRS,4SR,7aRS)-4-(3-Chlorophenylethynyl)-4-hydroxy-octahydro-indole-1-carboxylic acid ethyl ester
(±)-(3aRS,4SR,7aRS)-4-(3-Fluoro-phenylethynyl)-4-hydroxy-octahydro-indole-1-carboxylic acid ethyl ester
(3aRS ,4SR, 7aRS)-4-Hydroxy-4-phenylethynyl-octahydro-indole-1 -carboxylic acid(S)(tetrahydrofuran-3-yl)ester
(3aRS,4SR,7aRS)-4-Hydroxy-4-phenylethynyl-octahydro-indole-1 -carboxylic acid(R)(tetrahydrofuran-3-yl)ester
(3aRS,4SR,7aRS)-4-Hydroxy-4-(3-chlorophenylethynyl)-octahydro-indol-1-carboxylic acid- (S)(tetrahydrofuran-3yl)ester
(±)-(3aRS,4SR,7aRS)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1 -carboxylic acid ethyl ester
(±)-(3aRS,4SR,7aRS)-4-(4-Fluoro-phenylethynyl)-4-hydroxy-octahydro-indole-1 -carboxylic acid ethyl ester
(±)-(3aRS,4SR,7aRSH-(3-cnloroPneny|ethynylH-nydroχy-1-methanesulfonyl-octahydro- indole
(±)-(3aRS,7aRS)-4-Phenylethynyl-2,3,3a,6,7,7a-hexahydro-indole-1 -carboxylic acid ethyl ester and (±)-(RS)-4-phenylethynyl-2,3, 5,6,7, 7a-hexahydro-indole-1 -carboxylic acid ethyl ester
(±)-(3RS,7aRS)-2,2,2-Trifluoro-1-(4-phenylethynyl-2,3,3a,6,7,7a-hexahydro-indol-1-yl)- ethanone (±)-(RS)-4-m-Tolylethynyl-2,3, 5, 6,7, 7a-hexahydro-indole-1 -carboxylic acid ethyl ester
(±)-(3RS,7aRS)-4-m-Tolylethynyl-2,3,3a,6,7,7a-hexahydro-indole-1 -carboxylic acid ethyl ester (+)-(3RS,7aRS)-4-(4-Chloro-phenylethynyl)-2,3,3a,6,7,7a-hexahydro-indole-1-carboxylic acid ethyl ester
(±)-(3RS,7aRS)-4-(2-Fluoro-phenylethynyl)-2,3,3a,6,7,7a-hexahydro-indole-1-carboxylic acid ethyl ester
(±HSRSJaRSH-CS-Fluoro-phenylethynyl^.S.Sa.ejJa-hexahydro-indole-i-carboxylic acid ethyl ester
(±)-(RS)-4-(3-Fluoro^henylethynyl)-2,3,5,6,7,7a-hexahydro-indole-1 -carboxylic acid ethyl ester
(±)-(3RS,7aRS)- 4-(3-Methoxy-phenylethynyl)-2,3,3a,6,7,7a-hexahydro-indole-1-carboxylic acid ethyl ester
(± )-(RS)-4-(3-Methoxy-phenylethynyl)-2, 3,5, 6,7,7a-hexahydro-indole-1 -carboxylic acid ethyl ester
(±)-(3aRS,4RS,7aSR)-4-Hydroxy-4-phenylethynyl-octahydro-isoindole-2-carboxylic acid ethyl ester
(±)-(3aRS,4RS,7aSR)-4-Hydroxy-4-m-tolylethynyl-octahydro-isoindole-2-carboxylic acid ethyl ester
(±)-(3aRS,4RS,7aSR)-4-Hydroxy-4-p-tolylethynyl-octahydro-isoindole-2-carboxyIic acid ethyl ester
(±)-{3aRS,4RS,7aSR)-4-(3-Cyano-phenylethynyl)-4-hydroxy-octahydro-isoindole-2- carboxylic acid ethyl ester
(±)-(3aRS,4RS,7aSR)-4-Hydroxy-4-(3-methoxy-phenylethynyl)-octahydro-isoindole-2- carboxylic acid ethyl ester
(±)-(3aRS,4RS,7aSR)-4-(3-Fluoro-phenylethynyl)-4-hydroxy-octahydro-isoindole-2- carboxylic acid ethyl ester
(+)-(3aRS,4RS,7aSR)-4-Hydroxy-4-phenylethynyl-octahydro-isoindole-2-carboxylic acid tert- butyl ester
(±)-(3aRS,4RS,7aSR)-4-Hydroxy-4-m-tolylethynyl-octahydro-isoindole-2-carboxylic acid tert- butyl ester
(±)-(3aRS,4RS,7aSR)-4-Hydroxy-4-m-tolylethynyl-octahydro-isoindole-2-carboxylic acid methyl ester
(±)-(3aRS,4RS,7aSR)-Furan-2-yl-(4-hydroxy-4-m-tolylethynyl-octahydro-isoindol-2-yl)- methanone
(±)-(3aRS,4RS,7aSR)-Cyclopropyl-(4-hydroxy-4-m-tolylethynyl-octahydro-isoindol-2-yl)- methanone (±)-(3aRS,4RS,7aSR)- (4-Hydroxy-4-m-tolylethynyl-octahydro-isoindol-2-yl)-pyridin-3-yl- methanone
(±)-((1SR,3SR)-3-Hydroxy-3-m-tolylethynyl-cyclohexyl)-methyl-carbamic acid methyl ester and (±)-((1RS,3SR)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-methyl-carbamic acid methyl ester
(±)-(1RS,3SR)-((3-Hydroxy-3-m-tolylethynyl-cyclohexyl)-(4-methoxy-benzyl)-carbamic acid ethyl ester
(±)-(1RS,3RS)-((3-Hydroxy-3-m-tolylethynyl-cyclohexyl)-(4-methoxy-benzyl)-carbamic acid ethyl ester
(±)-[(1RS,3SR)-3-Hydroxy-3-(3-methoxy-phenylethynyl)-5,5-dimethyl-cyclohexyl]-methyl- carbamic acid methyl ester
(±)-(1RS,3SR)-(3-Hydroxy-5,5-dimethyl-3-m-tolylethynyl-cyclohexyl)-methyl-carbamic acid methyl ester
(±)-[(1 RS,3SR)-3-(3-Fluoro-phenylethynyl)-3-hydroxy-5,5-dimethyl-cyclohexyl]-methyl- carbamic acid methyl ester
(±)-[(1 RS,3RS)-3-(3-Fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-methyl-carbamic acid methyl ester
(±)-[(1 RS,3SR)-3-(3-Fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-methyl-carbamic acid methyl ester
(±)-[(1 RS,3RS)-3-Hydroxy-3-(3-methoxy-phenylethynyl)-cyclohexyl]-methyl-carbamic acid methyl ester
(±)-[(1 RS,3SR)-3-Hydroxy-3-(3-methoxy-phenylethynyl)-cyclohexyl]-methyl-carbamic acid methyl ester
(±)-[(1 RS,3RS)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-methyl-carbamic acid methyl ester
(±)-[(1 RS,3SR)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-methyl-carbamic acid methyl ester
(±)-(1RS,3RS)-N-(3-hydroxy-3-m-tolylethynyl-cyclohexyl)-acetamide (±)-(1RS,3SR)-N-(3-hydroxy-3-m-tolylethynyl-cyclohexyl)-acetamide (±)-(1RS,3RS)-(3-Hydroxy-3-m-tolylethynyl-cyclohexyl)-carbamic acid ethyl ester (±)-(1RS,3SR)-(3-Hydroxy-3-m-tolyiethynyl-cyclohexyl)-carbamic acid ethyl ester (±)-(1RS,3RS)-[3-(3-Fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-carbamic acid ethyl ester (±)-(1RS,3SR)-[3-(3-Fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-carbamic acid ethyl ester (±)-(1 RS,3RS)-[3-(3-Methoxy-phenylethynyl)-3-hydroxy-cyclohexyl]-carbamic acid ethyl ester
(iHIRS^RSJ-N-p^a-Fluoro-phenylethynyl^a-hydroxy-cyclohexylJ-acetamide. (±)-(1RS,3SR)-N-[3-(3-Fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-acetamide (±)-(1 RS,3SR)-[3-Hydroxy-3-(3-methoxy-phenylethynyl)-cyclohexyl]-carbamic acid ethyl ester
(±)-(1RS,3RS)-N-[3-Hydroxy-3-(3-methoxy-phenylethynyl)-cyclohexyl]-acetamide (±)-(1RS,3SR)-N-[3-Hydroxy-3-(3-methoxy-phenylethynyl)-cyclohexyl]-acetamide. (±)-(1 RS,3RS)-[3-Hydroxy-3-(3-methoxy-phenylethynyl)-cyclohexyl]-carbamic acid te/t-butyl ester (±)-(1 RS,3SR)-[3-Hydroxy-3-(3-methoxy-phenylethynyl)-cyclohexyl]-carbamic acid ferf-butyl ester
(±)-(1RS,3RS)-(3-Hydroxy-3-m-tolylethynyl-cyclohexyl)-carbamic acid tert-butyl ester (±)-(1RS,3SR)-(3-Hydroxy-3-m-tolylethynyl-cyclohexyl)-carbamic acid tert-butyl ester (±)-(1 RS,3RS)-(3-(3-Fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-carbamic acid tert-butyl ester (±)-(1 RS,3SR)-(3-(3-Fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-carbamic acid tert-butyl ester
(±)-(1RS,3RS)-[3-(3-Fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-carbamic acid methyl ester (±)-(1RS,3SR)-[3-(3-Fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-carbamic acid methyl ester (±)-(3-Phenylethynyl-cyclohex-2-enyl)-carbamic acid ethyl ester and (±)-3-phenylethynyl- cyclohex-3-enyl)-carbamic acid ethyl ester
(±)-Methyl-(3-phenylethynyl-cyclohex-3-enyl)-carbamic acid ethyl ester (±H^aRS.SRS.δaSRJ-S-Hydroxy-S-phenylethynyl-octahydro-quinoline-i-carboxylic acid ethyl ester (±)-[(4aRS,5SR,8aSR)- 5-(3-Chloro-phenylethynyl)-5-hydroxy-octahydro-quinolin-1-yl]-furan-
2-yl-methanone (±)-[(4aRS,5RS,8aSR)-5-(3-Chloro-phenylethynyl)-5-hydroxy-octahydro-quinolin-1-yl]-furan-
2-yl-methanone (±)-(4aRS,5RS,8aSR)-5-(3-Chloro-phenylethynyl)-5-hydroxy-octahydro-quinoline-1- carboxylic acid tert-butyl ester (±)-[(4aRS,5SR,8aSR)-5-(3-Chloro-phenylethynyl)-5-hydroxy-octahydro-quinolin-1-yl]- morpholin-4-yl-methanone
(±)-[(4aRS,5SR,8aSR)-5-(3-chloro-phenylethynyl)-5-hydroxy-octahydro-quinolin-1-yl]-(4- methyl-piperazin-1-yl)-methanone (±J^aRS.SRS.δaSRJ-δ^S-chloro-phenylethynyO-S-hydroxy-octahydro-quinoline-i- carboxylic acid ethyl ester and (±)-(4aRS,5SR,8aSR)- 5-(3-chloro-phenylethynyl)-5-hydroxy- octahydro-quinoline-1-carboxylic acid ethyl ester
(±)-(4aRS,5SR,8aSR)- δ-Hydroxy-S-m-tolylethynyl-octahydro-quinoline-i -carboxylic acid ethyl ester
(±)-(4aRS,5RS,8aSR)- 5-Hydroxy-5-m-tolylethynyl-octahydro-quinoline-1 -carboxylic acid ethyl ester.
In a further embodiment, the mGluR modulator is a compound of the formula (V), for exaple, as described in WO 2006/114262:
Figure imgf000016_0001
wherein
R1 represents hydrogen or alkyl;
R2 represents an unsubstituted or substituted heterocycle or
R2 represents an unsubstituted or substituted aryl;
R3 represents alkyl or halogen;
X represents a single bond or an alkandiyl-group, optionally interrupted by one or more oxygen atoms or carbonyl groups or carbonyloxy groups in free base or acid addition salt form.
Exemplary compounds of formula (V) include:
Furan-3-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
Furan-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
Furan-2-carboxylic acid [(IS^SJ-S-^-chloro-phenylethynyO-S-hydroxy-cyclohexyll-amide
3H-lmidazole-4-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide 3H-lmidazole-4-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
4H-[1 ,2,4]Triazole-3-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
4H-[1 ,2,4]Triazole-3-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
2-Methyl-furan-3-carboxylic acid [(±)-(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-[(±)-(1R,3R)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-3,4-difluoro-benzamide Benzo[1 ,3]dioxole-2-carboxylic acid [(±)-(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide δ-Methyl-pyrazine^-carboxylic acid [(±)-(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
Quinoxaline-2-carboxylic acid [(±)-(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
Benzofuran-2-carboxylic acid [(±)- (1R,3R)-3-(3-chioro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
Benzooxazole-2-carboxylic acid [(±)- (1R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexylj-amide
2,5-Dimethyl-furan-3-carboxylic acid [(±)- (1R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
(R.SJ-Tetrahydro-furan-S-carboxylic acid [(±)-(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexylj-amide
Furan-3-carboxylic acid ((1 R,3R)-3-hydroxy-3-m-toiylethynyl-cyclohexyl)-amide Furan-3-carboxylic acid ((1 S,3S)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide Furan-3-carboxylic acid ((±)-(1 R.SRJ-S-hydroxy-S-m-tolylethynyl-cyclohexyO-amide Furan-2-carboxylic acid ((1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide Furan-2-carboxylic acid ((1 S,3S)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide Furan-2-carboxylic acid ((±)-(1 R.SRVS-hydroxy-S-m-tolylethynyl-cyclohexyO-amide lsoxazole-5-carboxylic acid ((1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide lsoxazole-5-carboxylic acid ((1 S,3S)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide lsoxazole-5-carboxylic acid ((±)-(1 R.SRVS-hydroxy-S-m-tolylethynyl-cyclohexyO-amide 5-Methyl-pyrazine-2-carboxylic acid ((±) -(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide 4H-[1 ,2,4]Triazole-3-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
SH-lmidazole^-carboxylic acid ((±)- (IR.SR^S-hydroxy-S-m-tolylethynyl-cyclohexyO-amide
Tetrahydro-pyran-4-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
1-Methyl-1 H-imidazole-4-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
(R,S)-Tetrahydro-furan-2-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl- cyclohexyl)-amide
(R,S)-Tetrahydro-furan-3-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl- cyclohexyl)-amide
Furan-3-carboxylic acid [(1 R.SRJ-S-CS-fluoro-phenylethynyO-S-hydroxy-cyclohexyll-amide Furan-3-carboxylic acid [(1S,3S)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide Furan-2-carboxylic acid [(1R,3R)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide Furan-2-carboxylic acid [(1 S,3S)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide 3H-lmidazole-4-carboxylic acid [(+)-(1 R,3R)-3-(3-fluoro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-KIS.SSVS^S-Chloro-phenylethynyO-S-hydroxy-cyclohexyll-S^-difluoro-benzamide N-[(1R,3R)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-3,4-difluoro-benzamide Pyridine-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide Pyridine-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide N-[(1R,3R)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide Benzo[1 ,3]dioxole-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
5-Methyl-pyrazine-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
2-Methyl-furan-3-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
(R)-Tetrahydro-furan-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
(S)-Tetrahydro-furan-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide lsoxazole-5-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide 5-Methyl-pyrazine-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
2-Methyl-furan-3-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyi]- amide lsoxazole-5-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
5-Chloro-furan-2-carboxylic acid [(1 R,3R)-3-(3-chioro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide .
5-Chloro-furan-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
(S)-Tetrahydro-furan-3-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
(R)-Tetrahydro-furan-3-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-isonicotinamide N-[(1R,3R)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-isonicotinamide S^-Difluoro-pyridine^-carboxylicacid [(1R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
S.δ-Difluoro-pyridine^-carboxylicacid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
6-Methyl-pyridine-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
6-Methyl-pyridine-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
5-Chloro-pyridine-2-carboxylic add [(1R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
5-Chloro-pyridine-2-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
G-Chloro-pyridine^-carboxylic acid [(1 R,3R)-3-(3-chloro-phenyiethynyl)-3-hydroxy- cyclohexyl]-amide θ-Chloro-pyridine^-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
5-Chloro-1-methyl-1H-pyrrole-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3- hydroxy-cyclohexyl]-amide 5<;hloro-1-methyl-1 H-pyrrole-2-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3- hydroxy-cyclohexyl]-amide
5-Chloro-1 H-pyrrole-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
5-Chloro-1 H-pyrrole-2-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-dimethyl amino-benzamide
1 H-Pyrrole-3-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hyd roxy-cyclohexyl]-amide
N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-methyl-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-methyl-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-3-fluoro-benzamide
N-^IS.SSJ-S-iS-Chloro-phenylethynyO-S-hydroxy-cyclohexyll^-ethyl-butyramide
N-[(1S,3S)-3-(3-Chloro-phenyiethynyl)-3-hydroxy-cyclohexyl]-4-(2,5-dimethoxy-phenyl)-4- oxo-butyramide
2-(2-Benzyloxy-ethoxy)-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- acetamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-phenyl-acetamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-3-(1H-indol-4-yl)-propionamide
2-Benzo[1,3]dioxol-5-yl-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- acetamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-phenoxy-propionamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-(2-fluoro-phenyl)-acetamide
5-Hydroxy-1 H-indole-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
1-Methyl-1 H-pyrrole-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-[(1 S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-terephthalamic acid methyl ester
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-(2-trifluoromethoxy-phenyl)- acetamide
5-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-hydroxy-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-hydroxy-benzamide N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-hydroxy-benzamide
4-Amino-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-benzamide
4-Amino-5-chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-
3-Amino-4-chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-benzamide
3-Amino-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-methyl-benzamide
2-Amino-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-hydroxy-3-methoxy- benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-fluoro-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-methanesulfonyl-benzamide
Pyridine-2-carboxylic acid [(1 S.SSJ-S-^-chloro-phenylethynyO-S-hydroxy-cyclohexyll-amide
3-Amino-pyrazine-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
6-Amino-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide
4-(4-Amino-benzoylamino)-benzoic acid [(1R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
2,6-Dioxo-1 ^.S.e-tetrahydro-pyrimidine^-carboxylic acid [(1 S,3S)-3-(3-chloro- phenylethynyl)-3-hydroxy-cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-isonicotinamide
3-Chloro-N-[(1S,3S)-3-{3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2,3-dimethoxy-benzamide
N-^I S.SSVS^S-Chloro-phenylethynylJ-S-hydroxy-cyclohexylJ^-oxo^-phenyl-butyramide
2-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide
5-Bromo-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide lsoquinoline-1-carboxylic acid [(IS.SS^S^S-chloro-phenylethynyO-S-hydroxy-cyclohexyl]- amide
Pyrazine-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
3-Benzoyl-pyridine-2-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-methyl-nicotinamide
Quinoxaline-2-carboxylic acid [(1 S.SSJ-S-^-chloro-phenylethynyO-S-hydroxy-cyclohexyl]- amide
Pyridazine-4-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-methylsulfanyl-nicotinamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-trifluoromethyl-nicotinamide
2-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-isonicotinamide
2-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexy!]-6-methyl-nicotinamide
6-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide
2-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-6-methyl- isonicotinamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-(4,5-dimethoxy-3-oxo-1 ,3- dihydro-isobenzofuran-1-yl)-acetamide
1 ,4,5,6-Tetrahydro-cyclopentapyrazole-3-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-
3-hydroxy-cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-3-(1H-indol-2-yl)-propionamide
6-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexylcarbamoyl]-pyridine-2-carboxylic acid isopropyl ester
Quinoline-6-carboxylic acid [(IS.SSJ-S^S-chloro-phenylethynylJ-S-hydroxy-cyclohexylJ-amide δ-Methyl-isoxazole^-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
Benzofuran-3-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-(2-methoxy-phenoxy)- acetamide.
In a further embodiment, the mGluR modulator is a compound of the formula (Vl)
Figure imgf000022_0001
wherein
R1 represents hydrogen or alkyl;
R2 represents an unsubstituted or substituted heterocycle or R2 represents an unsubstituted or substituted aryl; R3 represents alkyl or halogen; in free base or acid addition salt form.
In another embodiment, the mGluR modulator is a compound of the formula (VII):
Figure imgf000023_0001
wherein
R1 represents hydrogen or alkyl;
R2 represents an unsubstituted or substituted heterocycle or R2 represents an unsubstituted or substituted aryl;
R3 represents alkyl or halogen;
X represents a single bond or an alkandiyl-group, optionally interrupted by one ore more oxygen atoms or carbonyl groups or carbonyloxy groups
in free base or acid addition salt form.
In a further embodiment, the invention provides a compound of formula (VIII)
Figure imgf000024_0001
wherein
R1 represents hydrogen or alkyl;
R2 represents an unsubstituted or substituted heterocycle or R2 represents an unsubstituted or substituted aryl;
R3 represents alkyl or halogen;
in free base or acid addition salt form.
Preferred substituents, preferred ranges of numerical values or preferred ranges of the radicals present in the formula (VII) and formula (VIII) are defined below.
R1 preferably represents hydrogen or C1^ alkyl.
R1 particularly preferably represents hydrogen.
R3 preferably represents Fluoro, Chloro, C1-4 alkyl.
R3 particularly preferably represents chloro or methyl.
R2 preferably represents an unsubstituted or substituted heterocycle having 3 - 11 ring atoms and 1 - 4 hetero atoms; the hetero atoms being selected from the group consisting of N, O, S, the substituents being selected from the group consisting of Oxo (=O), Hydroxy, Halogen, Amino, Nitro, Cyano, Ci-4 Alkyl, C1^ Alkoxy, C1^ Alkoxyalkyl, Ci_4 Alkoxycarbonyl, C1^ Alkoxycarbonylalkyl, C1-4 Halogenalkyl, C6.10 Aryl, Halogen- C6-IO Aryl, C6-10 Aryloxy, C6-10-A^l-C1-4 alkyl.
R2 further preferably represents phenyl or substituted phenyl, the substituents being selected from the group consisting of Hydroxy, Amino, Halogen, Nitro, Cyano, C1-4 Alkyl, C1.4 Alkoxy, C1.4 Alkoxyalkyl, C1^ Alkoxycarbonyl, Ci-4 Alkoxycarbonylalkyl, Ci.4 Halogenalkyl, C6-io Aryl, Halogen- C6-10 Aryl, C6-10 Aryloxy, C6-I0-A^l-C1 ^ alkyl.
R2 particularly preferably represents an unsubstituted, a single or twofold substituted heterocycle having 5 - 9 ring atoms and 1 - 3 hetero atoms; the hetero atoms being selected from the group consisting of N, O; the substituents being selected from the group consisting of Halogen, C1^ Alkyl.
R2 particularly preferably represents an unsubstituted, a single or twofold substituted phenyl, the substituents being selected from the group consisting of fluoro, chloro, hydroxy, methyl, methoxy, methoxycarbonyl, trifluormethoxy, amino, dimethylamino, methylthio, methylsulfonyl.
R2 very particularly preferably represents an unsubstituted, a single or twofold substituted heterocycle selected from the group consisting of
Figure imgf000026_0001
and the substituents selected from the group consisting of fluoro, chloro, methyl, methylthio, amino.
R2 further very particularly preferably represents a substituent selected from the group consisting of
Figure imgf000026_0002
X preferably represents C^alkandiyl, C^ alkandiyl with an oxygen group at the end or C^alkandiyl with an carbonyl group at the end, C1-6 alkandiyl with an carbonyloxy group at the end.
X particular preferably represents, methandiyl (-CH2-), 1 ,2-ethanediyl (-CH2-CH2-), 1,1- ethanediyl ((-CH(CH3)-), , methandiyloxy (-0-CH2-), 1 ,2-ethanediyloxy (-0-CH2-CH2-), 1 ,1-ethanediyloxy ((-0-CH(CH3)-), methandiylcarbonyl (-CO-CH2-), 1 ,2- ethanediylcarbonyl (-CO-CH2-CH2-), 1,1-ethanediylcarbonyl ((-CO-CH(CH3)-), methandiylcarbonyloxy (-C(O)O-CH2-), 1,2-ethanediylcarbonyloxy (-C(O)O-CH2-CH2-), 1 ,1-ethanediylcarbonyloxy ((-C(O)O-CH(CH3)-). The functional groups as defined for X are preferably bound to the group R2.
The abovementioned general or preferred radical definitions can be combined with one another at will, i.e. including combinations between the given preferred ranges. Further, individual definitions may not apply.
Preference according to the invention is given to compounds of the formula (VII) which contain a combination of the meanings mentioned above as being preferred.
Particular preference according to the invention is given to compounds of the formula (VII) which contain a combination of the meanings listed above as being particularly preferred.
Very particular preference according to the invention is given to the compounds of the formula (VII) which contain a combination of the meanings listed above as being very particularly preferred.
Preferred are compounds of formula (VII) wherein R2 represents an unsubstituted or substituted heterocycle.
In a further embodiment, the invention provides a compound of formula (IX)
Figure imgf000027_0001
wherein R1 and R2 are as defined above.
In a further embodiment, the invention provides a compound of formula (IX) as defined above, wherein R2 is as defined above and R1 represents hydrogen.
Examples of compounds of formula (VII), (VIII) and (IX) include: Furan-3-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
Furan-3-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
Furan-2-carboxylic acid [(1 R.SRVS-P-chloro-phenylethynyO-S-hydroxy-cyclohexylJ-amide
Furan-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
SH-lmidazole^-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
3H-lmidazole-4-carboxylic acid [(IS.SSJ-S-P-chloro-phenylethynyO-S-hydroxy-cyclohexyl]- amide
4H-[1 ,2,4]Triazole-3-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
4H-[1 ,2,4]Triazole-3-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
2-Methyl-furan-3-carboxylic acid [(±)-(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-^±HIR.SRJ-S^S-Chloro-phenylethynyO-S-hydroxy-cyclohexyll-S^-difluoro-benzamide
Benzo[1 ,3]dioxole-2-carboxylic acid [(±)-(1 R,3R)-3-(3-chloro-phenylethynyi)-3-hydroxy- cyclohexylj-amide
5-Methyl-pyrazine-2-carboxylic acid [(±)-(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexylj-amide
Quinoxaline-2-carboxylic acid [(±)-(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
Benzofuran-2-carboxylic acid [(±)- (1R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
Benzooxazole-2-carboxylic acid [(±)- (1R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
2,5-Dimethyl-furan-3-carboxylic acid [(±)- (1R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
(R.SJ-Tetrahydro-furan-S-carboxylic acid [(±)-(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
Furan-3-carboxylic acid ((1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide
Furan-3-carboxylic acid ((1 S,3S)-3-hydroxy-3-m-tolylethynyl-cyclohexy!)-amide
Furan-3-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide
Furan-2-carboxylic acid ((1 R.SRJ-S-hydroxy-S-m-tolylethynyl-cyclohexyO-amide
Furan-2-carboxylic acid ((1 S,3S)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide Furan-2-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide lsoxazole-5-carboxylic acid ((1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide lsoxazole-5-carboxylic acid ((1 S,3S)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide lsoxazole-5-carboxylic acid ((±)-(1 R.SRVS-hydroxy-S-m-tolylethynyl-cyclohexyO-amide
5-Methyl-pyrazine-2-carboxylic acid ((±) -(1R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
4H-[1 ,2,4]Triazole-3-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
3H-lmidazole-4-carboxylic acid ((±)- (1R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)-amide
Tetrahydro-pyran-4-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
1-Methyl-1 H-imidazole-4-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
(R,S)-Tetrahydro-furan-2-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
(R.SJ-Tetrahydro-furan-S-carboxylic acid ((±)-(1 R,3R)-3-hydroxy-3-m-tolylethynyl-cyclohexyl)- amide
Furan-3-carboxylic acid [(1 R,3R)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
Furan-3-carboxylic acid [(1 S,3S)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
Furan-2-carboxylic acid [(1 R,3R)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
Furan-2-carboxylic acid [(1 S,3S)-3-(3-fluoro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
3H-lmidazole-4-carboxylic acid [(±)-(1 R,3R)-3-(3-fluoro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-3,4-difluoro-benzamide
N-[(1R,3R)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-3,4-difluoro-benzamide
Pyridine-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
Pyridine-2-carboxyiic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide
N-[(1 R,3R)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide
Benzo[1 ,3]dioxole-2-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
5-Methyl-pyrazine-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide 2-Methyl-furan-3-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
(R)-Tetrahydro-furan-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
(S)-Tetrahydro-furan-2-carboxyiic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide lsoxazole-5-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
5-Methyl-pyrazine-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenyiethynyl)-3-hydroxy- cyclohexyl]-amide
2-Methyl-furan-3-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide lsoxazole-5-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
5-Chloro-furan-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
5-Chloro-furan-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
(S)-Tetrahydro-furan-3-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
(R)-Tetrahydro-furan-3-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-isonicotinamide
N-[(1R,3R)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-isonicotinamide
S.S-Difluoro-pyridine^-carboxylicacid [(1R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
3,5-Difluoro-pyridine-2-carboxylicacid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
6-Methyl-pyridine-2-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
6-Methyl-pyridine-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
5-Chloro-pyridine-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
5-Chloro-pyridine-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexylj-amide 6-Chloro-pyridine-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide θ-Chloro-pyridine^-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
5-Chloro-1-methyl-1H-pyrrole-2-carboxylic acid [(1R,3R)-3-(3-chloro-phenylethynyl)-3- hydroxy-cyclohexyl]-amide
5-Chloro-1-methyl-1 H-pyrrole-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3- hydroxy-cyclohexyl]-amide
5-Chloro-1 H-pyrrole-2-carboxylic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
5-Chloro-1 H-pyrrole-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-dimethyl amino-benzamide
1 H-Pyrrole-3-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hyd roxy-cyclohexyl]-amide
N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-methyl-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-methyl-benzamide
N-[(1S,3S)-3-(3-ChIoro-phenylethynyl)-3-hydroxy-cyclohexyl]-3-fluoro-benzamide
N-^IS.SSJ-S^S-Chloro-phenylethynyO-S-hydroxy-cyclohexylJ^-ethyl-butyramide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-(2,5-dimethoxy-phenyl)-4- oxo-butyramide
2-(2-Benzyloxy-ethoxy)-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- acetamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-phenyl-acetamide
N-^IS.SSJ-S^S-Chloro-phenylethynyO-S-hydroxy-cyclohexylj-S^IH-indoM-yO-propionamide
2-Benzo[1 ,3]dioxol-5-yl-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- acetamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-phenoxy-propionamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-(2-fluoro-phenyl)-acetamide
S-Hydroxy-IH-indole^-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
1-Methyl-1 H-pyrrole-2-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-terephthalamic acid methyl ester
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-(2-trifluoromethoxy-phenyl)- acetamide
5-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-hydroxy-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-hydroxy-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-hydroxy-benzamide
4-Amino-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-benzamide
4-Amino-5-chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-methoxy- benzamide
3-Amino-4-chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-benzamide
3-Amino-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-methyl-benzamide
2-Amino-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-hydroxy-3-methoxy- benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-fluoro-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-methanesulfonyl-benzamide
Pyridine-2-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide
S-Amino-pyrazine^-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
6-Amino-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide
4-(4-Amino-benzoylamino)-benzoic acid [(1 R,3R)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
2,6-Dioxo-1 ,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid [(1 S,3S)-3-(3-chloro- phenylethynyl)-3-hydroxy-cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-isonicotinamide
3-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2,3-dimethoxy-benzamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-4-oxo-4-phenyl-butyramide
2-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide
5-Bromo-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide lsoquinoline-1-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
Pyrazine-2-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-amide 3-Benzoyl-pyridine-2-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-methyl-nicotinamide
Quinoxaline-2-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
Pyridazine-4-carboxylic acid [(1 S.SSJ-S-^-chloro-phenylethynylJ-S-hydroxy-cyclohexyl]- amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-methylsulfanyl-nicotinamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyciohexyl]-4-trifluoromethyl-nicotinamide
2-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-isonicotinamide
2-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-6-methyl-nicotinamide
6-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-nicotinamide
2-Chloro-N-[(1S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-6-methyl- isonicotinamide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-(4,5-dimethoxy-3-oxo-1 ,3- dihydro-isobenzofuran-1-yl)-acetamide
1 ,4,5,6-Tetrahydrc-cyclopentapyrazole-3-carboxylic acid [(1S,3S)-3-(3-chloro-phenylethynyl)-
3-hydroxy-cyclohexyl]-amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-3-(1H-indol-2-yl)-propionamide
6-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexylcarbamoyl]-pyridine-2-carboxylic acid isopropyl ester
Quinoline-6-carboxylic acid [(1 S^SJ-S-^-chloro-phenylethynylJ-S-hydroxy-cyclohexylJ-amide
5-Methyl-isoxazole-4-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy- cyclohexyl]-amide
Benzofuran-3-carboxylic acid [(1 S,3S)-3-(3-chloro-phenylethynyl)-3-hydroxy-cyclohexyl]- amide
N-[(1S,3S)-3-(3-Chloro-phenylethynyl)-3-hydroxy-cyclohexyl]-2-(2-methoxy-phenoxy)- acetamide.
Further examples of mGluR, in particular mGluR5, modulators include compounds of the formula (I) as defined in WO 2004/014881 and compounds of the formula (I) as defined in WO 2007/021575; the contents of these publications are incorporated herein by reference. Compounds of the invention and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties and are therefore useful as pharmaceuticals.
Compounds of the invention may exhibit a marked and selective modulating, especially antagonistic, action at human mGluRs, in particular mGluRδs. This can be determined in vitro for example at recombinant human metabotropic glutamate receptors, especially PLC- coupled subtypes thereof such as mGluR5, using different procedures like, for example, measurement of the inhibition of the agonist induced elevation of intracellular Ca2+ concentration in accordance with L. P. Daggett et al., Neuropharm. Vol. 34, pages 871-886 (1995), P. J. Flor et al., J. Neurochem. Vol. 67, pages 58-63 (1996) or by determination to what extent the agonist induced elevation of the inositol phosphate turnover is inhibited as described by T. Knoepfel et al., Eur. J. Pharmacol. Vol. 288, pages 389-392 (1994), L. P. Daggett et al., Neuropharm. Vol. 67, pages 58-63 (1996) and references cited therein. Isolation and expression of human mGluR subtypes are described in US-Patent No. 5,521 ,297. Selected agents of the invention show IC50 values for the inhibition of the agonist (e.g. glutamate or quisqualate) induced elevation of intracellular Ca2+ concentration or the agonist (e.g. glutamate or quisqualate) induced inositol phosphate turnover, measured in recombinant cells expressing hmGluRδa of about 1 nM to about 50 μM.
Compounds of the invention are useful in the treatment, prevention or delay of progression of cognitive dysfunction. Cognitive dysfunction include deficits and abnormalities in attention and vigilance, executive functions and memory (for instance working memory and episodic memory). Other disorders relating to cognitive dysfunction include sleep related breathing disorders (SRBD), behavioural impairments, information processing deficits and age-related disorders.
Further examples of cognitive impairment and related disorders include attention-deficit hyperactivity disorder (ADHD), childhood ADHD, adult ADHD, excess daytime somnolence, sleep apnea, shift-worker's sleep-wake cycle disruption, traumatic brain injury, neurodegenerative disorders with associated memory and cognitive problems (such as Alzheimer's disease, Lewy body dementia, senile dementia, vascular dementia, Parkinson's disease), chronic fatigue syndrome, fatigue associated with sleep deprivation or prolonged wakefulness, age-related decline in memory and cognitive function (such as mild cognitive impairment), cognitive impairment associated with mood disorders (such as depression) and anxiety, schizophrenia and day time sleepiness associated with narcolepsy.
Treatment may comprise cognitive enhancement. The term "cognitive enhancement" includes, but is not limited to, cognition enhancement, vigilance, counteracting effects of fatigue, enhancing alertness, attention, memory (working, episodic), learning ability, reaction time, cognitive performance enhancement, excess daytime somnolence, reversal of information processing deficits, improvement of disorganization, i.e. improving organizational skills/level of organizational ability.
For the above-mentioned indications (the conditions and disorders) the appropriate dosage will vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.01 to about 100 mg/kg body weight, preferably from about 0.1 to about 10 mg/kg body weight, e.g. 1 mg/kg. In larger mammals, for example humans, an indicated daily dosage is in the range from about 0.1 to about 1000 mg, preferably from about 1 to about 400 mg, most preferably from about 10 to about 100 mg of an mGluR, e.g. mGluR5, antagonist or other modulator conveniently administered, for example, in divided doses up to four times a day.
For use according to the invention, an mGluR modulator (e.g. an mGluR5 modulator, in particular an mGluR5 antagonist) may be administered as single active agent or in combination with other active agents, in any usual manner, e.g. orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injection solutions or suspensions.
Moreover, the present invention provides a pharmaceutical composition comprising an mGluR modulator (e.g. an mGluR5 modulator, in particular an mGluR5 antagonist) in association with at least one pharmaceutical carrier or diluent for use in the treatment of cognitive dysfunction. Such compositions may be manufactured in conventional manner. Unit dosage forms may contain, for example, from about 2.5 to about 25 mg of one or more mGluR modulator, e.g. mGluR5 antagonist or other modulator. The usefulness of the compounds of the invention in the treatment of the above-mentioned disorders can be confirmed in a range of standard tests including those indicated below:
The pharmaceutical compositions according to the invention are compositions for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (human beings and animals) that comprise an effective dose of the pharmacological active ingredient alone or together with a significant amount of a pharmaceutically acceptable carrier. The dose of the active ingredient depends on the species of warm-blooded animal, body weight, age and individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
The pharmaceutical compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragees, tablets or capsules.
The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
The following non-limiting Examples illustrate the invention. Further preparations of the mGluR modulators as described herein may be found in other publications, such as , WO 2005/079802, WO 2003/047581 , WO 2004/000316, WO 2005/044265, WO 2005/044266, WO 2005/044267, WO 2006/114262 and WO 2007/071358. As such, the following Examples are considered to be non limiting to the other compounds of the invention, A list of abbreviations used is given below.
AcOH acetic acid
BOC tert-butoxycarbonyl n-BuLi n-butyl lithium
DMF N,N'-dimethylformamide
EDC 1 -ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride
HOBt hydroxybenzotriazole
AcN acetonitrile BINAP (2,2'-bis(diphenylphosphino)-1 ,1'-binaphthyl
DAST (Diethylamino)sulfur trifluoride
DCE 1 ,2-dichloroethane
DCM dichloromethane
DIPEA N,N-diisopropylethylamine
DMA N,N-dimethylacetamide
DMAP 4-N,N-dimethylaminopyridine
DME 1 ,2-dimethoxyethane
DMSO dimethylsulfoxide
EtOAc ethylacetate
ESI electrospray ionization h hours
HCI hydrochloric acid
HATU N-[(dimethylamino)-1H-1 ,2,3-triazolo[4,5-b]pyridine-1-ylmethylene]-Λ/-methyl methanaminium hexafluorophosphate Λ^-oxide
HMPA hexamethylphosphoramide
HPLC high pressure liquid chromatography min minutes
Mp melting point
MS mass spectroscopy
MTBE methyl-tert. -butylether
Rf retention factor (Thin Layer Chromatography) rt room temperature tR retention time
TFA trifluoroacetic acid
THF tetrahydrofuran
HPLC specificity
System 1 : System 1 : Performed on a Waters system equipped with a CTC Analytics HTS PAL autosampler, 515 pumps, and a 996 DAD detector operating at 210 nm. Column: CC70/3 Nucleosil 100-3 C18 (3 μ, 70 x 3 mm, Macherey-Nagel, order # 721791.30), temperature: 45°C, flow: 1.2 mL min"1. Eluents: A: Water + 0.2% H3PO4 (85%, (Merck 100552) + 2% Me4NOH, (10%, Merck 108123), B: Acetonitrile + 20% water + 0.1% H3PO4 (85%) + 1% Me4NOH (10%). Gradient: 0% B to 95% B within 6.6 min., then 95% B 4.4 min. System 2: Gilson 331 pumps coupled to a Gilson UV/VIS 152 detector and a Finnigan AQA spectrometer (ESI), a 50 μl_ loop injection valve and a Waters XTerra MS C18 3.5 μm 4.6x50 mm column running a gradient from 5% to 90% acetonitrile containing 0.05% TFA.
System 3: Agilent 1100 Series, LC-MSD and a Agilent Zorbax SB-C18 3x30mm 1.8μm
Column running a gradient Water + 0.05% TFA / Acetonitrile + 0.05% TFA from 100/0 to
0/100 over 3.25' - 0/100 over 0.75' - 0/100 to 90/10 over 0.25' with a flux of 0.7 ml/min,
35°C.
System 4: Agilent 1100 Series, LC-MSD and a Agilent Zorbax SB-C18 3x30mm 1.8μm
Column running a gradient Water + 0.05% TFA / Acetonitrile + 0.05% TFA from 90/10 to
0/100 over 3.25' - 0/100 over 0.75' - 0/100 to 70/30 over 0.25' with a flux of 0.7 ml/min,
35°C.
System 5: Agilent 1100 Series, LC-MSD and a Agilent Zorbax SB-C18 3x30mm 1.8μm
Column running a gradient Water + 0.05% TFA / Acetonitrile + 0.05% TFA from 70/30 to
0/100 over 3.25' - 0/100 over 0.75' - 0/100 to 60/40 over 0.25' with a flux of 0.7 ml/min,
35°C.
System 6: Agilent 1100 Series, LC-MSD and a Agilent Zorbax SB-C18 3x30mm 1.8μm
Column running a gradient Water + 0.05% TFA / Acetonitrile + 0.05% TFA from 30/70 to
0/100 over 3.25' - 0/100 over 0.75' - 0/100 to 90/10 over 0.25' with a flux of 0.7 ml/min,
35°C.
Example 1.1 : 6-(4-Chloro-phenylamino)-N, N-diethyl-nicotinamide hydrochloride 6-Chloro-N,N-diethyl-nicotinamide (100 mg, 0.47 mmol) and 4-chloroaniline (184 mg, 1.41 mmol) are suspended in a mixture of glacial acetic acid (0.6 mL) and water (1.4 mL). The reaction mixture is heated in a sealed 3 mL-vial to 100 0C over night. After reaching room temperature the reaction mixture is poured onto MTBE (30 mL) and extracted with 2M HCI (3x 5 mL). The combined acidic extracts are made alkaline by addition of 2M NaOH (10 mL) extracted with MTBE (3x 15 mL). The combined organic extracts are dried (Na2SO4) and evaporated to dryness to. The residue is purified by flash-chromatography. To the combined product containing fractions is added 4M HCI in dioxane (0.25 mL) followed by evaporation. The residue is triturated with ether, filtered off, washed with cold ether and vacuum dried at 45 0C to give the title compound as colorless crystals (90 mg, 56%). TLC: Rf = 0.16 (MTBE), HPLC: tR = 6.0 min, (system 1 ); ESI+ MS: m/z = 304.5 (MH+).
The starting material can be prepared as described hereafter: 6-Chloro-N,N-diethyl-nicotinamide
Under Ar, chloronicotinoyl chloride (4 g, 22 mmol) is suspended in DCM (40 ml_). The reaction flask is placed in an ice bath and a solution of diethylamine (2.31 ml_, 22 mmol) and triethylamine (3.90 ml_, 27.8 mmol) in DCM (40 ml_) is added within 45 min keeping the internal temperature below 5 0C. The ice bath is removed and the reaction mixture is stirred for further 30 min. The solution is washed (1x water (40 mL), 1x 1M Na2CO3 (40 ml_), 1x water (40 mL)), dried over Na2SO4 and evaporated to dryness to afford a reddish orange oil (4.50 g, 95%) which can be used without further purification.
Following the same procedure, the following compounds can be prepared:
Example 1.2: N,N-Diethyl-6-p-tolylamino-nicotinamide hydrochloride
Yellowish lyophilisate, TLC: Rf = 0.22 (MTBE), HPLC: tR = 5.5 min, (system 1); ESI+ MS: m/z
= 284.6 (MH+).
Example 1.3: N, N-Diethyl-6-(4-methoxy-phenylamino) -nicotinamide hydrochloride
Light gray crystals, TLC: Rf = 0.14 (MTBE), HPLC: tR = 4.6 min, (system 1 ); ESI+ MS: m/z =
300.6 (MH+).
Example 1.4: 6-(4-Chloro-phenylamino)-N,N-bis-(2-methoxy-ethyl)-nicotinamide hydrochloride
Yellowish lyophilisate, TLC: R, = 0.10 (MTBE), HPLC: tR = 5.6 min, (system 1); ESI+ MS: m/z
= 364.5 (MH+).
Example 1.5: [6-(4-Chloro-3-fluoro-phenylamino)-pvridin-3-yll-piperidin-1-yl-methanone Colorless crystals, HPLC: tR = 6.6 min, (system 1 ); ESI+ MS: m/z = 334.5 (MH+).
Example 1.6: [6-(4-Bromo-phenylamino)-pyridin-3-yl]-piperidin- 1 -yl-methanone
Colorless crystals, TLC: Rf = 0.31 (MTBE-ETOAC 9:1 ), HPLC: tR = 6.3 min, (system 1 ); ESI+
MS: m/z = 360.6 (MH+).
Example 1.7: 4-[5-(Piperidine-1-carbonyl)-pyridin-2-ylamino]-benzonitrile Colorless crystals, TLC: R, = 0.14 (MTBE), HPLC: tR = 5.7 min, (system 1 ); ESI+ MS: m/z = 307.6 (MH+).
Example 1.8: Piperidin- 1 -yl-[6-(4-trifluoromethoxy-phenylamino)-pyridin-3-yl]-methanone Colorless crystals, TLC: R, = 0.29 (DCM-ETOAC 7:3), HPLC: tR = 6.6 min, (system 1 ); ESI+ MS: m/z = 366.7 (MH+).
Example 1.9: [6-(4-Chloro-phenylamino)-pyridin-3-yl]-(2-methyl-piperidin- 1 -yl)-methanone hydrochloride
TLC: R, = 0.23 (MTBE), HPLC: tR = 6.5 min, (system 1); ESI+ MS: m/z = 330.5 (MH+).
Example 1.10: (2-Methyl-piperidin-1-yl)-(6-p-tolylamino-pyridin-3-yl)-methanone
Beige crystals, TLC: Rf = 0.24 (MTBE), HPLC: fe = 6.0 min, (system 1); ESI+ MS: m/z =
310.5 (MH+).
Example 1.11: [6-(4-Methoxv-phenvlamino)-pvridin-3-vll-(2-methyl-piperidin-1-vl)-methanone hydrochloride
Purple crystals, TLC: Rf = 0.27 (MTBE), HPLC: tR = 5.4 min, (system 1); ESI+ MS: m/z =
326.5 (MH+).
Example 1.12: rac-[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(3-methyl-piperidin- 1 -yl)- methanone
Colorless crystals, TLC: Rf = 0.25 (MTBE), HPLC: tR = 6.6 min, (system 1); ESI+ MS: m/z =
330.5 (MH+).
Using either S-3-methylpiperidine or R-3-methylpiperidine as starting material the pure enantiomers could be prepared:
[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(S-3-methyl-piperidin-1-yl)-methanone
Colorless crystals, TLC: Rf, = 0.22 (MTBE), HPLC: tR = 6.7 min, (system 1 ); ESI+ MS: m/z =
330.1 (MH+).
[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(R-3-methyl-piperidin-1-yl)-methanone
Beige crystals, HPLC: tR = 6.7 min, (system 1 ); ESI+ MS: m/z = 330.2 (MH+).
Example 1.13: 3-Methyl-piperidin-1-yl)-(6-p-tolylamino-pyridin-3-yl)-methanone Pink lyophilisate, HPLC: tR = 6.2 min, (system 1); ESI+ MS: m/z = 310.5 (MH+). Example 1.14: [6-(4-Methoxy-phenylamino)-pvridin-3-vl]-(3-methyl-piperidin-1-vl)-methanone hydrochloride
Brown crystals, HPLC: tR = 5.6 min, (system 1); ESI+ MS: m/z = 326.5 (MH+).
Example 1.15: (3-Methyl-piperidin- 1 -yl)-(6-pherιylamino-pyridin-3-yl)-methanone hydrochloήde
Colorless crystals, TLC: Rf = 0.26 (MTBE), HPLC: ^ = 5.8 min, (system 1); ESI+ MS: m/z =
296.5 (MH+).
Example 1.16: [6-(3-Chloro-phenylamino)-pyridin-3-yl]-(3-methyl-piperidin- 1 -yl)-methanone hydrochloride
TLC: R, = 0.27 (MTBE), HPLC: tR = 6.6 min, (system 1); ESI+ MS: m/z = 330.5 (MH+).
Example 1.17: [6-(4-Chloro-phenvlamino)-Dvridin-3-vll-morpholin-4-yl-methanone hydrochloride
Yellowish crystals, TLC: R, = 0.38 (MTBE-MeOH 9:1), HPLC: fo = 5.5 min, (system 1 ); ESI+
MS: m/z = 318.5 (MH+).
Example 1.18: [6-(4-Methoxv-phenvlamino)-pvridin-3-vl]-morpholin-4-yl-methanone hydrochloride
Greenish solid, TLC: R, = 0.35 (MTBE-MeOH 9:1 ), HPLC: tR = 4.0 min, (system 1 ); ESI+ MS: m/z = 314.5 (MH+).
Example 1.19: cis-[6-(4-Chloro-phenylamino)-pyridin-3~yl]-(2,6-dimethyl-morpholin-4-yl)- methanone hydrochloride
Colorless crystals, TLC: R, = 0.13 (MTBE), HPLC: tR = 6.1 min, (system 1 ); ESI+ MS: m/z =
346.5 (MH+).
Example 1.20: (cis-2,6-Dimethyl-morpholin-4-vl)-(6-p-tolvlamino-pvridin-3-yl)-methanone hydrochloride
Beige crystals, TLC: Rf = 0.24 (MTBE), HPLC: tR = 5.4 min, (system 1 ); ESI+ MS: m/z =
326.6 (MH+). Example 1.21 : (cis-2β-Dimethyl-morpholin-4-yl)-[6-(4-methoxy-phenylamino)-pyπdin-3-yl]- methanone hydrochloride
Purple crystals, TLC: Rf = 0.16 (MTBE), HPLC: tR = 4.9 min, (system 1); ESI+ MS: m/z = 342.5 (MH+).
Example 2.1 : [6-(5-Chloro-pvridin-2-vlamino)-pvridin-3-vlJ-piperidin-1-vl-methanone A solution of palladium(ll) acetate (2 mg, 9 μmol) and BINAP (5.6 mg, 9 μmol) in dry and degassed toluene (1.5 mL) is stirred for 10 min under Ar. Then, the clear yellow solution obtained is added to a degassed suspension of (6-chloro-pyridin-3-yl)-piperidin-1-yl- methanone (100 mg, 0.45 mmol, prepared according to the general procedure stated in example 1.1 ), 2-amino-5-chloropyridine (70 mg, 0.53 mmol), and KOfBu (257 mg, 2.22 mmol) in dry toluene. The reaction mixture is stirred for 5 h in a sealed 5 mL-vial. After reaching room temperature the mixture is poured into MTBE (30 mL), washed (3x H2O (20 mL)), dried over Na2SO4 and evaporated to give a turbid oil. Crystallization from Et2O affords the title compound as beige crystals (87 mg, 62%), HPLC: tR = 4.8 min, (system 1 ); ESI+ MS: m/z = 317.6 (MH+).
Following the same procedure, the following compounds can be prepared:
Example 2.2: Azepan- 1 -yl-[6-(pyridin-3-ylamino)-pyridin-3-yl]-methanone
Yellowish lyophilisate, TLC: R, = 0.28 (MTBE-MeOH 85:15), HPLC: tR = 4.2 min, (system 1 );
ESI+ MS: m/z = 297.2 (MH+).
Example 2.3: [6-(3.4-Difluoro-Dhenvlamino)-Dvridin-3-vll-DiDeridin-1-vl-methanone Colorless crystals, HPLC: tR = 6.1 min, (system 1); ESI+ MS: m/z = 318.6 (MH+).
Example 2.4: rac-(2-Aza-bicyclo[2.2. IJhept^-ylj-fS-chloro-e-ft-chloro-phenylaminoj-pyridin-
3-yl]-methanone
Beige powder, HPLC: tR = 6.9 min, (system 1 ); ESI+ MS: m/z = 364.0 (MH+).
Example 2.5: f5-Chloro-6-(4-chloro-phenvlamino)-Dvridin-3-vll-thiomorpholin-4-yl-methanone Beige powder, HPLC: tR = 6.6 min, (system 1 ); ESI+ MS: m/z = 370.0 (MH+). Example 2.6: rac-fi-Chloro-β-fβ-methoxy-pyridin-S-ylaminoj-pyridin-S-ylJ-fS-methyl-piperidin-
1-yl)-methanone
Beige lyophilisate, TLC: Rf = 0.49 (MTBE), HPLC: tR = 6.2 min (system 1 ); ESI+ MS: m/z =
361.1 (MH+).
Example 2.7: Azepan-1-vl-fδ-chloro-6-(6-methoxv-pvridin-3-vlamino)-pyridin-3-vl]-methanone Beige lyophilisate, TLC: Rf = 0.32 (MTBE), HPLC: tR = 6.0 min (system 1 ); ESI+ MS: m/z = 361.1 (MH+).
Example 2.8: [δ-Chloro-β-fβ-methoxy-pyridin-S-ylaminoj-pyridin-S-ylJ-piperidin- 1 -yl- methanone
Colorless lyophilisate, TLC: Rf = 0.36 (MTBE), HPLC: tR = 5.9 min (system 1 ); ESI+ MS: m/z
= 347.0 (MH+).
Example 2.9: [δ-Chloro-β-fβ-ethoxy-pyridinS-ylaminoJ-pyridin-S-ylJ-piperidin- 1 -yl-methanone Colorless lyophilisate, TLC: Rf = 0.23 (EtOAc/hexanes 1:1), LC/MS: m/z = 361 (MH+).
Example 2.10: rac-fi-Chloro-β-fβ-methyl-pyridin-S-ylaminoj-pyridin-S-ylJ-fi-methyl-piperidin-
1-yl)-methanone
Beige crystals, HPLC: tR = 4.7 min (system 1 ); ESI+ MS: m/z = 345.1 (MH+).
Using either S-3-methylpiperidine or /?-3-methylpiperidine as starting material the pure enantiomers could be prepared:
Example 2.10a: fδ-Chloro-6-(6-methyl-pyridin-3-vlamino)-pyridin-3-vl1-(S-3-methyl-piperidin-
1-yl)-methanone
Brown gum, HPLC: tR = 4.7 min (system 1 ); ESI+ MS. m/z = 345.1 (MH+)
Example 2.10b: fδ-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-vll-(R-3-methyl-piperidin-
1-yl)-methanone
Brown gum, HPLC: tR = 4.5 min (system 1 ); ESI+ MS. m/z = 345.1 (MH+)
Example 2.11: [δ-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-DiDeridin-1-yl- methanone
Colorless crystals, HPLC: tR = 4.3 min (system 1 ); ESI+ MS: m/z = 331.1 (MH+). Example 2.12: Azepan- 1 -yl-lδ-chloro-β-fβ-methyl-pyridin-S-ylaminoj-pyήdin-S-ylj-methanone Colorless crystals, HPLC: tR = 4.3 min (system 1); ESI+ MS: m/z = 345.1 (MH+).
Example 2.13: rac-(2-Aza-bicyclo[2.2.1]hept-2-yl)-[5-chloro-6-(6-methyl-pyridin-3-ylamino)- pyridin-3-yl]-methanone
Beige powder, HPLC: tR = 4.1 min (system 1); ESI+ MS: m/z = 343.1 (MH+).
Example 2.14: fδ-Chloro-6-(6-methvl-pvridin-3-vlamino)-pyridin-3-vl]-thiazolidin-3-vl- methanone
Beige powder, HPLC: tR - 4.1 min (system 1 ); ESI+ MS: m/z = 335.0 (MH+).
Example 2.15: fδ-Chloro-6-(6-methvl-pvπdin-3-vlamino)-pvridin-3-vl]-thiomorpholin-4-yl- methanone
Beige powder, HPLC: tR = 3.9 min (system 1 ); ESI+ MS: m/z = 349.0 (MH+).
Example 2.16: fδ-Chloro-6-(2-methvl-pvrimidin-δ-vlamino)-pvridin-3-vlh(3-methyl-piperidin-1- yl)-methanone
Colorless crystals, HPLC: tR = 5.6 min (system 1); ESI+ MS: m/z = 346.1 (MH+).
Example 2.17: [δ-Chloro-β-ft-methyl-pyrimidin-δ-ylaminoj-pyridinS-ylJ-piperidin- 1 -yl- methanone
Colorless crystals, HPLC: tR = 5.1 min (system 1); ESI+ MS: m/z = 332.1 (MH+).
Example 2.18: Azepan-1-vl-[δ-chloro~6-(2-methvl-pvrimidin-δ-γlamino)-pvridin-3-vll- methanone
Colorless crystals, HPLC: tR = 5.5 min (system 1); ESI+ MS: m/z = 346.1 (MH+).
Example 2.19: fi-Chloro-β-fβ-methyl-pyridinS-ylaminof-pyridinS-ylJ-ft-ethyl-piperidin- 1 -yl)- methanone
A mixture of (S^-dichloro-pyridin-S-ylHS-ethyl-piperidin-i-ylJ-methanone (300 mg, 1.04 mmol), 3-amino-6-methyl pyridine (171 mg, 1.57 mmol), Pd(OAc)2 (7 mg, 0.03 mmol), rac- BINAP (20 mg, 0.03 mmol) and potassium carbonate (723 mg, 5.2 mmol) in degassed toluene (10 mL) was stirred, under argon, at 800C for 3 hours. EtOAc was added and the organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to give a crude beige powder. The crude material was sonicated in pentane/Et2O and then filtered. After high-vacuum drying, [5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(3- ethyl-piperidin-1-yl)-methanone (100 mg, 27%) was obtained as a beige powder. (ES-MS: m/z 359.3/361.3 [M+H]\ tR 3.52 min (system 2)).
The starting material was prepared as described hereafter:
i) 3-ethyl piperidine
3-Ethyl pyridine (5.0 g, 46.7 mmol) was hydrogenated in AcOH (100 mL) over PtO2 (500 mg) under 4 bar for 4 hours. The mixture was filtered through a pad of celite and washed with AcOH. The solvent was removed in vacuo and the residue was dissolved into water. The solution was basified by addition with 40% NaOH solution. The aqueous phase was extracted with Et2O. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford 3-ethyl piperidine (4.4 g, 83%) as a clear yellow oil.
ii) (5,6-Dichloro-pyridin-3-yl)-(3-ethyl-piperidin-1-yl)-methanone
A mixture of 5,6 dichloronicotinic acid (1 g, 5.2 mmol) in SOCI2 (6 mL) was stirred at 700C for 4 hours. The solvent was removed in vacuo to give a beige oil (1.05 g) corresponding to the acid chloride. This oil was solublised in DCM (15 mL) and at 00C triethylamine (1.1 mL, 7.84 mmol) was added. Then, a solution of 3-ethyl piperidine (657 mg, 5.75 mmol) in DCM (5 mL) was added carefully drop-wise. At the end of the addition, the mixture was stirred at RT for 30 min. Water was added and the aqueous phase was extracted with DCM. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to (5,6- dichloro-pyridin-3-yl)-(3-ethyl-piperidin-1-yl)-methanone (1.2 g, 80%) as a yellow oil. (ES-MS: m/z 328.2/330.2 [M+CH3CN+ H]+, tR 5.48 min (system 2)).
Example 2.20: [5-Chloro-6-(6-methoxy-pyridin-3-ylamino)-pyridin-3-yl]-(3-ethyl-piperidin-1-yl)- methanone
A mixture of (5,6-dichloro-pyridin-3-yl)-(3-ethyl-piperidin-1-yl)-methanone (300 mg, 1.04 mmol), 5-amino-2-methoxy pyridine (201 mg, 1.57 mmol), Pd(OAc)2 (7 mg, 0.03 mmol), rac- BINAP (20 mg, 0.03 mmol) and potassium carbonate (723 mg, 5.2 mmol) in degassed toluene (10 ml_) was stirred, under argon, at 800C for 3 hours. EtOAc was added and the organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to give a crude beige powder. The crude material was purified by flash chromatography using EtOAc/Hexanes as eluent to afford [5-chloro-6-(6-methoxy-pyridin-3-ylamino)-pyridin-3- yl]-(3-ethyl-piperidin-1-yl)-methanone (60 mg, 15%) as a beige powder. (ES-MS: m/z 375.3/375.5 [M+H]\ tR 5.21 min (system 2))
Example 2.21 : [S-Chloro-β-ft-chloro-phenvlaminoϊ-pvridin-S-vll-fS-ethyl-piperidin-i-vl)- methanone
A mixture of (5,6-dichloro-pyridin-3-yl)-(3-ethyl-piperidin-1-yl)-methanone (300 mg, 1.04 mmol), 4-chloro aniline (206 mg, 1.57 mmol), Pd(OAc)2 (7 mg, 0.03 mmol), rac-BINAP (20 mg, 0.03 mmol) and potassium carbonate (723 mg, 5.2 mmol) in degassed toluene (10 ml_) was stirred, under argon, at 800C for 3 hours. EtOAc was added and the organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to give a crude beige powder. The crude material was purified by flash chromatography using EtOAc/Hexanes as eluent to afford [5-chloro-6-(4-chloro-phenylamino)-pyridin-3-yl]-(3-ethyl- piperidin-1-yl)-methanone (150 mg, 38%) as a beige powder. (ES-MS: m/z 378.2/380.3 [M+H]\ tR 6.50 min (system 2))
Example 2.22: f5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-ylH3-propyl-piperidin-1-yl)- methanone
A mixture of (5,6-dichloro-pyridin-3-yl)-(3-propyl-piperidin-1-yl)-methanone (440 mg, 1.26 mmol), 3-amino-6-methyl pyridine (210 mg, 1.88 mmol), Pd(OAc)2 (8.6 mg, 0.03 mmol), rac- BINAP (24 mg, 0.03 mmol) and potassium carbonate (879 mg, 5.0 mmol) in degassed toluene (10 ml_) was stirred, under argon, at 800C for 3 hours. EtOAc was added and the organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to give a crude beige powder. The crude material was purified by flash chromatography using EtOAc/Hexanes as eluent to afford [5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3- yl]-(3-propyl-piperidin-1-yl)-methanone (110 mg, 23%) as a beige powder. (ES-MS: m/z 373.3/375.3 [M+H]\ tR 4.52 min (system 2))
The starting material was prepared as described hereafter: i) 3-propyl pyridine
At 00C, to a mixture of diisopropylamine (3.53 ml_, 24.7 mmol) in THF (35 mL), BuLi (1.6 M in hexanes, 15.4 mL, 25 mmol) was added drop-wise. After 30 min, HMPA (15.7 g, 24.7 mmol) was aded and the mixture was kept at 00C for 15 min. Then a solution of 3-methyl pyridine (2.3 g, 24.7 mmol) in THF (10 mL) was added drop-wise. After 30 min, EtI (3.45 g, 24.7 mmol) in THF (10 mL) was added drop-wise and the mixture was then stirred at RT for 1 hour. The mixture was poured into 10% HCI. The aqueous phase was extracted with Et2O. The organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to afford a yellow oil (300 mg, 10%) which will be used without further purification.
ii) 3-propyl piperidine
3-propyl pyridine (300 mg, 2.48 mmol) was hydrogenated in AcOH (20 mL) over PtO2 (50 mg) under 4 bar for 16 hours. The mixture was filtered through a pad of celite and washed with AcOH. The solvent was removed in vacuo and the residue was dissolved into water. The solution was basified by addition with 40% NaOH solution. The aqueous phase was extracted with Et2O. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford 3-propyl piperidine (300 mg, 95%) as a clear yellow oil.
Ni) (δ.δ-Dichloro-pyridin-S-ylHS-propyl-piperidin-i-ylJ-rnethanone
5,6-Dichloro-nicotinoyl chloride (550 mg, 2.61 mmol) was solubilised in DCM (15 mL) and at 00C triethylamine (0.54 mL, 3.95 mmol) was added. Then, a solution of 3-propyl piperidine (369 mg, 2.87 mmol) in DCM (5 mL) was added carefully drop-wise. At the end of the addition, the mixture was stirred at RT for 30 min. Water was added and the aqueous phase was extracted with DCM. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford a beige-brown oil. This oil was sonicated in pentane to afford (5,6-dichloro-pyridin-3-yl)-(3-propyl-piperidin-1-yl)-methanone (440 mg, 48%) as a beige- brown solid.
Example 2.23: rδ-Chloro-β-fβ-trifluoromethvl-pyridin-S-vlaminoj-ovridin-S-vll-ffRΪ^-ethvl- piperidin-1 -yl)-methanone
LC/MS: m/z = 413 (MH+); TLC: R, = 0.40 (DCM/MeOH 95:5). Example 2.24: [S-Chloro-β-fβ-methoxy-pyridin-S-vlaminohpyridin-S-yiπfRl^-ethyl-piperidin-
1-yl)-methanone
LC/MS: m/z = 375 (MH+); TLC: R, = 0.40 (DCM/MeOH 95:5).
Example 3.1 : rac-I5-Chloro-6-(6-methvl-pvridin-3-vloxv)-pyridin-3-vlh(3-methvl-piperidin-1-vl)- methanone
To a solution of rac-(5,6-dichloropyridin-3-yl)-(3-methyl-piperidin-1-yl)-methanone (50 mg, 0.18 mmol, prepared according to the procedure stated in example 1.1) and 4-chlorophenol (23.5 mg, 0.18 mmol) in dry DMA (1 rtiL) is added finely ground anhydrous K2CO3 (50.6 mg, 0.36 mmol). The suspension is microwave heated to 140 0C in a sealed 5 mL-vial for 45 min with stirring. Then, the reaction mixture is diluted with ethyl acetate (10 ml_) and washed with brine (10 ml_). The organic layer is dried (Na2SO4) and evaporated to dryness to give a brown oil. Purification by preparative HPLC afforded the title compound as colorless syrup (40 mg, 60%), HPLC: tR = 7.1 min (system 1 ); ESI+ MS: m/z = 365.0 (MH+).
Following the same procedure, the following compounds can be prepared:
Example 3.2: f5-Chloro-6-(6-methyl-pvridin-3-vloxv)-pvridin-3-yl]-piperidin-1-yl-methanone Colorless syrup, HPLC: tR - 6.8 min (system 1); ESI+ MS: m/z = 351.0 (MH+).
Example 3.3: Azepan-1-yl-[5-chloro-6-(6-methyl-pyridin-3-yloxy)-pyridin-3-ylhmethanone Colorless syrup, HPLC: tR = 7.0 min (system 1); ESI+ MS: m/z = 365.0 (MH+).
Example 4.1 : [6~(6-Methyl-pvridin-3-ylamino)-pyridin-3-yl]-piperidin-1-vl-methanone To 6-(6-methyl-pyridin-3-ylamino)-nicotinic acid (210 mg, 0.92 mmol) is added thionyl chloride (2 mL). The colorless suspension is refluxed under argon for 20 min. After cooling the excess thionyl chloride is stripped off. The residue is redissolved in DCM (6 mL) and a solution of piperidine (0.11 mL, 1.10 mmol) and triethylamine (1.28 mL, 9.16 mmol) in DCM (2 mL) is quickly added. The yellow slightly turbid solution is stirred for 20 min at room temperature. Then, MTBE (60 mL) is added and the solution is extracted twice with water and brine. The organic layer is dried over Na2SO4 and evaporated to give a yellow foam. Flash chromatography (20 g silica gel, MeOH-MTBE gradient 2% -> 15% MeOH, flow 20 mL min"1) followed by crystallization from ether affords the title compound as colorless crystals (573 mg, 63%), TLC: R, = 0.18 (MTBE-MeOH 9:1 ), HPLC: tR = 3.8 min (system 1 ); ESI+ MS: m/z = 297.5 (MH+).
The starting material can be prepared as described hereafter: i) Methyl 6-(6-Methyl-pyridin-3-ylamino)-nicotinate
To 5-amino-2-methylpyridine (2.22 g, 20.56 mmol) and finely ground anhydrous K2CO3 (11.9 g, 85.2 mmol) is added dry toluene (30 mL) under argon. Then, a solution of palladium(ll) acetate (79 mg, 0.34 mmol) and BINAP (218 mg, 0.34 mmol) in dry toluene (10 mL) is added. The reaction mixture is placed in an oil bath (70 0C) and a solution of methyl 6- chloronicotinate (3.0 g, 17.1 mmol) in dry toluene (20 mL) is added dropwise within 30 min. After 1.5 h the oilbath is removed and the reaction flask is placed in an ice bath. After stirring for 15 min the product is filtered off. The filter cake is triturated three times with THF / MeOH 1:1 (100 mL). The combined extracts are evaporated to dryness to give a brown powder. Flash chromatography (gradient MTBE-MeOH 100:0 - MTBE-MeOH 85:15) followed by crystallization from ether gives the product as light pink crystals (1.86 g, 45%).
ii) 6-(6-Methyl-pyridin-3-ylamino)-nicotinic acid
To a suspension of methyl 6-(6-Methyl-pyridin-3-ylamino)-nicotinate (2.72 g, 11.18 mmol) in methanol (55 mL) is added 2M NaOH (17 mL). The reaction mixture is heated to 60 °C for 30 min. After 15 min a clear reddish solution is formed. Then, the reaction flask is placed in an ice bath and 2M HCI (17 mL) is added at such a rate that the internal temperature does not exceed 200C. After evaporation of methanol the suspension is diluted with water (50 mL). The product is filtered off, washed with cold water and vacuum dried at 600C over night to give a pink powder (2.78 g, 100%).
Following the same procedure, the following compounds can be prepared:
Example 4.2: Azepan-1-vl-f6-(4-chloro-Dhenvlamino)-pvridin-3-vll-methanone
Yellow foam, TLC: R, = 0.25 (MTBE), HPLC: tR = 6.5 min (system 1); ESI+ MS: m/z = 330.5
(MH+).
Example 4.3: [6-(4-Chloro-phenylamino)-pyridin-3-yl]-(3, 3-difluoro-piperidin- 1 -yl)- methanone Colorless crystals, TLC: Rt = 0.23 (MTBE), HPLC: tR = 6.1 min (system 1); ESI+ MS: m/z = 352.6 (MH+).
Example 4.4: l6-(4-Chloro-phenylamino)-pyridin-3-yl]-(4-methyl-piperidin-1-yl)-methanone Colorless crystals, TLC: Rf = 0.3 (MTBE), HPLC: tR = 6.6 min (system 1 ); ESI+ MS: m/z = 330.6 (MH+).
Example 4.5: f6-(4-Chloro-phenvlamino)-pyridin-3-yl]-(3,5-dimethyl-piperidin-1-yl)-methanone (diastereomeric mixture cis / trans 72:28)
Colorless crystals, TLC: Rf = 0.35 (MTBE), HPLC: tR = 6.9 min (trans diastereomer, 28%), 7.0 min (cis diastereomer, 72%) (system 1); ESI+ MS: m/z = 344.6 (MH+).
Example 4.6: rac-f6-(4-Chloro-phenylamino)-pyridin-3-yl]-(3-hydroxymethyl-piperidin-1-vl)- methanone
Colorless foam, TLC: R, = 0.32 (MTBE-MeOH 9:1), HPLC: fe = 5.2 min (system 1); ESI+ MS: m/z = 346.5 (MH+).
Example 4.7: rac-(6-(4-Chloro-phenylamino)-pyridin-3-vll-(3-methoxv-piperidin-1-yl)- methanone
Colorless foam, TLC: R, = 0.43 (MTBE-MeOH 9:1), HPLC: tR = 5.8 min (system 1 ); ESI+ MS: m/z = 346.5 (MH+).
Example 4.8: fβ^-Chloro-phenylaminoj-pyridinS-ylNoctahydro-Quinolin-i-yD-meth anone (diastereomeric mixture, cis / trans)
Colorless foam, TLC: R, = 0.22, 0.29 (MTBE-MeOH 9:1), HPLC: tR = 7.3 min (system 1 ); ESI+ MS: m/z = 370.7 (MH+).
Example 4.9: (3-Aza-bicyclo[3.2.2Jnon-3-yl)-[6-(4-chloro-phenylamino)-pyridin-3-yl]- methanone
Foam, TLC: R, = 0.28 (MTBE), HPLC: tR = 6.9 min (system 1); ESI+ MS: m/z = 356.6 (MH+).
Example 4.10: (2-Aza-tricyclo[3.3.1.1*3, 7*]dec-2-yl)-[6-(4-chloro-phenylamino)-pyridin-3-yl]- methanone Colorless crystals, TLC: R, = 0.23 (MTBE), HPLC: tR = 7.0 min (system 1 ); ESI+ MS: m/z = 368.6 (MH+).
Example 4.11 : [6'(4-Chloro-phenylamino)-pyridin-3-yl]-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8- yl)-methanone
Colorless foam, TLC: R, = 0.36 (MTBE-MeOH 9:1), HPLC: tR = 5.4 min (system 1); ESI+ MS: m/z = 358.6 (MH+).
Example 4.12: rac-(2-Aza-bicyclo[2.2.1]hept-2-yl)-[6-(4-chloro-phenylamino)-pyridin-3-yl]- methanone
Colorless crystals, TLC: Rf = 0.31 (MTBE-MeOH 95:5), HPLC: tR = 6.2 min (system 1 ); ESI+
MS: m/z = 328.6 (MH+).
Example 4.13: rac-(3-Methyl-piperidin- 1 -yl)-[6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]- methanone
Yellow foam, TLC: R, = 0.26 (MTBE-MeOH 9:1), HPLC: tR = 4.4 min (system 1); ESI+ MS: m/z = 311.6 (MH+).
Using either S-3-methylpiperidine or R-3-methylpiperidine as starting material the pure enantiomers could be prepared:
Example 4.13a: (S-3-Methyl-piperidin- 1 -yl)-[6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]- methanone
Colorless foam, TLC: R, = 0.32 (MTBE-MeOH 85:15), HPLC: fe = 4.1 min (system 1 ); ESI+
MS: m/z = 311.2 (MH+).
Example 4.13b: (R-3-Methyl-piperidin- 1 -yl) -[6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]- methanone
Colorless foam, HPLC: tR = 4.1 min (system 1); ESI+ MS: m/z = 311.2 (MH+).
Example 4.14: [6-(4-Chloro-phenylamino)-pyridin-3-yl]-(rel-(3aR, 4S, 7aR)-4-hydroxy-4-m- tolylethynyl-octahydro-indol-1-yl)-methanone
Yellow foam, TLC: R, = 0.32 (MTBE-MeOH 95:5), HPLC: fe = 6.8 min (system 1); ESI+ MS: m/z = 486.7 (MH+).
Example 4.15: Azepan- 1 -yl-[6-(6-methyl-pyridin-3-ylamino) -pyridin-3-yl]-methanone Yellow crystals, TLC: R, = 0.2 (MTBE-MeOH 9:1 ), HPLC: tR = 4.0 min (system 1 ); ESI+ MS: m/z = 311.6 (MH+).
Example 4.16: Azocan-1-vH6-(6-methvl-pvridin-3-vlamino)-pvridin-3-yl]-methanone
TLC: Rf = 0.33 (MTBE-MeOH 85:15), HPLC: tR = 4.5 min (system 1); ESI+ MS: m/z = 325.6
(MH+).
Example 4.17: f5-Chloro-6-(6-methvl-Dvridin-3-vlamino)-pvridin-3-vll-(2-ethyl-DiDeridin-1-vl)- methanone
TLC: R, = 0.13 (DCM/MeOH 95:5), HPLC: fe = 2.8 min (system 4); LC/MS MS: m/z = 359
(MH+).
Example 4.18: [5-Ch\oro-6-(β-methy\-pyπd\n-3-y\amino)-pyήdin-3-y\]-((R)-2-ethy\-pψ' eήd\n- 1 - yl)-methanone
TLC: R, = 0.81 (DCM/MeOH 5:1), HPLC: tR = 2.8 min (system 4); LC/MS MS: m/z = 359
(MH+); [α]D = -33.6° (c=1.0, CHCI3, 20 "C).
Example 4.19: [5-Chloro-6-(6-methvl-pvridm' -3-vlamino)-Dvridin-3-vlh((S)-2-ethyl-DiDeridin-1- yl)-methanone
TLC: R, = 0.81 (DCM/MeOH 95:5), HPLC: tR = 2.8 min (system 4); LC/MS MS: m/z = 359
(MH+), [α]Hg578 = +1 -64° (c=0.16, DCM, 20 0C).
Example 4.20: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-yll-(2.3-dimethvl-DiDeridin-
1-yl)-methanone
TLC: R, = 0.75 (DCM/MeOH 5:1), HPLC: tR = 2.8 min (system 4); LC/MS MS: m/z = 359
(MH+).
Example 4.21 : [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((2S, 3S)-2, 3-dimethyl- piperidin- 1 -yl)-methanone
TLC: Rf = 0.66 (DCM/MeOH 5:1 ), HPLC: tR = 2.76 min (system 4); LC/MS MS: m/z = 359 (MH+), [α]Hg578 = +0.9° (c=0.11 , DCM, 20 "C).
Example 4.22: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((2R, 3R)-2, 3-dimethyl- piperidin-1 -yl)-methanone TLC: Rf = 0.72 (DCM/MeOH 5:1), HPLC: tR = 2.76 min (system 4); LC/MS MS: m/z = 359 (MH+), [α]Hg578 = -1.0° (c=0.11 , DCM, 20 X).
Example 4.23: fδ-Chloro-β-fβ-methvl-pvridin-S-vlaminoi-pyridin-S-viπfS^-methvl-piperidin-
1-yl)-methanone
TLC: R, = 0.87 (DCM/MeOH 5:1), HPLC: tR = 2.65 min (system 4); LC/MS MS: m/z = 345
(MH+), [α]Hg578 = +0.10° (c=0.67, DCM, 20 0C).
Example 4.24: \5-Ch\oro-6-(Q-methy\-pyndin-3-y\am\no)-pyrid\n-3-y\]-UR)-2-methy\-p\peήdin-
1-yl)-methanone
TLC: R, = 0.80 (DCM/MeOH 5:1), HPLC: tR = 2.65 min (system 4); LC/MS MS: m/z = 345
(MH+), [α]Hg578 = -0.10° (c=0.67, DCM, 20 0C).
Example 4.25: [δ-Chloro-β-fβ-methyl-pyήdinS-ylaminoi-pyridin-S-vll-foctahvdro-filpvrindin-i- yl)-methanone
TLC: R, = 0.79 (DCM/MeOH 5:1), HPLC: tR = 2.76 min (system 4); LC/MS MS: m/z = 371
(MH+).
Example 4.26: [5-Chloro-6-(6-methyl-pvήdin-3-vlamino)-pyridin-3-ylh(4aS, 7aS)-octahydro- [1]pyrindin- 1 -yl-methanone
TLC: Rf = 0.64 (DCM/MeOH 5:1), HPLC: tR = 2.86 min (system 4); LC/MS MS: m/z = 371 (MH+), +0.12° (c=0.007, DCM, 20 0C).
Example 4.27: f5-Chloro-6-(6-methyl-pyήdin-3-vlamino)-pyπdin-3-yll-(4aR, 7aR)-octahydro- [1]pyrindin- 1 -yl-methanone
TLC: Rf = 0.64 (DCM/MeOH 5:1 ), HPLC: tR = 2.84 min (system 4); LC/MS MS: m/z = 371 (MH+), [α]Hg578 = -0.15° (c=0.007, DCM, 20 0C).
Example 4.28: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-isopropyl-pipehdin- 1 - yl)-methanone
TLC: R, = 0.76 (DCM/MeOH 5:1 ), HPLC: tR = 2.90 min (system 4); LC/MS MS: m/z = 373
(MH+). Ej(^mg\e_4^29i [5-Chloro-6-(6-methylψyridin-3-ylamino)-pyridin-3-yl]-((R)-2-isopropyl- piperidin- 1 -yl)-methanone
TLC: R, = 0.63 (DCM/MeOH 5:1), HPLC: tR = 2.88 min (system 4); LC/MS MS: m/z = 373 (MH+), [α]Hg578 = +0.72° (c=0.09, DCM, 20 0C).
Example 4.30: [5-Chloro-6-(6-methyl-pyridin~3-vlamino)-pyridin-3-yll-((S)-2-isopropyl- piperidin- 1 -yl)-methanone
TLC: R, = 0.63 (DCM/MeOH 5:1), HPLC: tR = 2.89 min (system 4); LC/MS MS: m/z = 373 (MH+), [α]Hg578 = -0.79° (c=0.09, DCM, 20 0C).
Example 4.31: (δ-Chloro-β-fβ-methyl-pyridin-S-ylaminoj-pyridin-S-yli-ffFD-S-ethyl-piperidin-i- yl)-methanone
TLC: R, = 0.30 (EtOAc/hexanes 1 :1 ), HPLC: tR = 2.83 min (system 4); LC/MS MS: m/z = 359
(MH+).
Example 4.32: fδ-Chloro-β-fβ-methyl-pyridin-S-ylaminohpyridin-S-yiπfShS-ethyl-piperidin-i- yl)-methanone
TLC: R, = 0.28 (EtOAc/hexanes 1 :1), HPLC: tR = 2.86 min (system 4); LC/MS MS: m/z = 359
(MH+).
Example 4.33: fδ-Chloro-6-(6-methyl-pyridin-3-ylamino)-Dyπdin-3-yl]-(3-cydθDrooyl-DiDeridin-
1-yl)-methanone
TLC: R, = 0.51 (DCM/MeOH 5:1), HPLC: tR = 2.90 min (system 4); LC/MS MS: m/z = 373
(MH+).
The starting material can be prepared as described hereafter:
[) 3-Cyclopropyl-piperidine hydrochloride
3-Cyclopropyl pyridine (820 mg, 5.27 mmol) was hydrogenated in a mixture of MeOH (15mL) and concentrated aqueous hydrochloric acid (0.58 mL) in the presence of Nishimura catalyst
(70 mg) under atmospheric pressure for 22 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM. The organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford 3-cyc!opropyl piperidine hydrochloride (694 mg, 82%) as colorless crystals. TLC: R, = 0.49 (DCM/MeOH 5:1 ), LC/MS MS: m/z = 126 (MH+).
Example 4.34: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vlM2-propyl-piperidin-1-yl)- methanone
TLC: R, = 0.84 (DCM/MeOH 5:1), HPLC: tR = 2.95 min (system 4); LC/MS MS: m/z = 373
(MH+).
Example 4.35: [δ-Chloro-β-fβ-methyl-pyridin-S-ylaminoj-pyridinS-ylJ-^S^-propyl-piperidin- 1 - yl)-methanone
TLC: R, = 0.69 (DCM/MeOH 5:1), HPLC: tR = 2.97 min (system 4); LC/MS MS: m/z = 373
(MH+), [α]Hg578 = +1.17" (c=0.09, DCM, 20 0C).
Example 4.36: [δ-Chloro-β-fβ-rnethyl-pyridin-S-ylaminohpyridin-S-vli-ffRl^-propyl-piperidin-
1-yl)-methanone
TLC: Rf = 0.61 (DCM/MeOH 5:1), HPLC: tR = 2.97 min (system 4); LC/MS MS: m/z = 373
(MH+), [α]Hg578 = -1 17° (c=0.09, DCM, 20 0C).
Example 4,37: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2, 3-diethyl-piperidin- 1 - yl)-methanone
TLC: R, = 0.21 (EtOAc/hexanes 1 :1 ), HPLC: tR = 3.08 min (system 4); LC/MS MS: m/z = 387
(MH+).
Example 4.38: (2-Butyl-piperidin-1-yl)-[5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]- methanone
TLC: Rf = 0.22 (DCM/MeOH 5:1), HPLC: tR = 3.09 min (system 4); LC/MS MS: m/z = 387
(MH+).
Example 4.39: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll-[2-(1-ethyl-propyl)- piperidin- 1 -yl]-methanone
TLC: R, = 0.87 (DCM/MeOH 95:5), HPLC: tR = 3.19 min (system 4); LC/MS MS: m/z = 401
(MH+). Example 4.40: fδ-Chloro-β-fβ-methyl-pvridin-S-ylaminoj-pyridin-S-vll^-ethyl-S-methvl- piperidin-1 -yl)-methanone
TLC: R, = 0.22 (EtOAc/hexanes 3:1), HPLC: tR = 2.89 min (system 4); LC/MS MS: m/z = 373
(MH+).
The starting material was prepared as described hereafter:
i) 2-Etyhl-3-methyl-pyridine
2-Ethyl-3-methylpyridine was prepared by Suzuki coupling of 2-bromo-3-methylpyridine and ethylboronic acid according to the procedure given in Tetrahedron Letters 2002, 43, 6987- 6990. The desired product was obtained in 52% yield after purification on silica gel.
ii) 2-Etyhl-3-methyl-piperidine hydrochloride
2-Ethyl-3-methyl pyridine (1.75 g, 11.1 mmol) was hydrogenated in a mixture of MeOH (32 mL) and concentrated aqueous hydrochloric acid (1.2 mL) in the presence of Nishimura catalyst (180 mg) under atmospheric pressure for 22 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM. The organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford 2-ethyl-3-methyl piperidine hydrochloride (1.60 g, 88%) as colorless crystals.
Example 4.41: [5-Chloro-6-(6-rnethvl-pvridin-3-vlamino)-pyridin-3-vl1-(2-phenvl-piperidin-1-vl)- methanone
TLC: R, = 0.34 (EtOAc/hexanes 3:1), HPLC: tR = 1.85 min (system 5); LC/MS MS: m/z = 407
(MH+).
Example 4.42: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(3, 4, 5, 6-tetrahydro-2H-
[2,2']bipyridinyl-1-yl)-methanone
TLC: Rf = 0.17 (EtOAc/hexanes 3:1), HPLC: tR = 2.29 min (system 5); LC/MS MS: m/z = 408
(MH+).
Example 4.43: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(3, 4, 5, 6-tetrahydro-2H- [2,3']bipyridinyl-1-yl)-methanone TLC: R, = 0.25 (DCM/MeOH 9:1 ), HPLC: fe = 2.11 min (system 5); LC/MS MS: m/z = 408 (MH+).
Example 4.44: ϊ5-Chloro-6-(6-methvl-Dvridin-3-vlamino)-pvridin-3-vl]-[2-(tetrahvdro-furan-2- yl)-piperidin- 1 -yl]-methanone
TLC: R, = 0.34 (DCM/MeOH 9:1 ), HPLC: tR = 2.62 min (system 4); LC/MS MS: m/z = 401
(MH+).
Example 4.45: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-ylM2-(5-methyl-furan-2-vl)- piperidin- 1 -yl]-methanone
TLC: R, = 0.63 (DCM/MeOH 9:1), HPLC: fo = 3.00 min (system 4); LC/MS MS: m/z = 411
(MH+).
Example 4.46: \5-Ch\oro-6-(Q-methw\-Dvridin-3-w\amino)-pyndin-3-y\]-(2-oxazo\-2-\/l-p\pendin-
1-yl)-methanone
TLC: R, = 0.55 (DCM/MeOH 9:1 ), HPLC: \R = 2.66 min (system 4); LC/MS MS: m/z = 414
(MH+).
Example 4.47: f2-(2-Chloro-ethvl)-Diperidin-1-vlJ-f5-chloro-6-(6-methvl'pvridin-3-vlamino)- pyridin-3-yl]-methanone
TLC: Rf = 0.33 (DCM/MeOH 5:1 ), HPLC: tR = 0.76 min (system 4); LC/MS MS: m/z = 394
(MH+).
Example 4.48: f5-Chloro-6-(6-methyl-pvridin-3-ylamino)-pyridin-3-yl]-(2.6-dimethyl-piperidin-
1-yl)-methanone
TLC: R, = 0.25 (EtOAc/hexanes 3:1 ), HPLC: tR = 3.03 min (system 3); LC/MS MS: m/z = 359
(MH+).
Example 4.49: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2, 2, 6, 6-tetramethyl- piperidin-1 -yl)-methanone
TLC: R, = 0.44 (EtOAc/hexanes 3:1 ), HPLC: fo = 3.14 min (system 4); LC/MS MS: m/z = 387
(MH+). Example 4.50: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll-(2-methyl-6-ropvl- piperidin-1 -yl)-methanone
TLC: R, = 0.35 (EtOAc/hexanes 3:1 ), HPLC: tR = 2.13 min (system 5); LC/MS MS: m/z = 387
(MH+).
Example 4.51 : [5-Chloro-6-(6-methvl-pvridin-3-ylamino)-pyridin-3-yl]-((2R,6R)-2-ethyl-6- propyl-piperidin-1-yl)-methanone
TLC: Rf = 0.45 (EtOAc/hexanes 3:1), HPLC: tR = 2.25 min (system 5); LC/MS MS: m/z = 387
(MH+).
Example 4.52: f5-Chloro-6-(6-methyl-pvridin-3-ylamino)-pyridin-3-yll-(5-methyl-2-ropyl- piperidin- 1 -yl)-methanone
TLC: R, = 0.40 (EtOAc/hexanes 3:1 ), HPLC: tR = 2.06 min (system 5); LC/MS MS: m/z = 387
(MH+).
The starting material was prepared as described hereafter:
i) 5-Methyl-2-propyl-pyridine
5-Methyl-2-propyl-pyridine was prepared by Suzuki coupling of 2-bromo-5-methylpyridine and propylboronic acid according to the procedure given in Tetrahedron Letters 2002, 43, 6987-6990. The desired product was obtained in 24% yield after purification on silica gel.
ii) 5-Methyl-2-propyl-piperidine hydrochloride
5-Methyl-2-propyl-pyridine (345 mg, 2.55 mmol) was hydrogenated in a mixture of MeOH (10 mL) and concentrated aqueous hydrochloric acid (0.29 mL) in the presence of Nishimura catalyst (50 mg) under atmospheric pressure for 40 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM. The organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford 2-methyl-3-propyl piperidine hydrochloride (0.43 g, 95%) as beige crystals.
Example 4.53: [δ-Chloro-β-M-chloro-phenvlaminoϊ-pvridin-S-yiπoctahvdro-ilpyrindin-i-yl)- methanone TLC: R, = 0.71 (DCM/MeOH 95:5), HPLC: tR = 3.85 min (system 5); LC/MS MS: m/z = 391 (MH+).
Example 4.54: fδ-Chloro-β-f^chloro-Dhenvlamino^Dvridin-S-vlJ-^RΪ-Σ-ethvl-piperidin-i-vl)- methanone
TLC: R, = 0.75 (DCM/MeOH 95:5), HPLC: tR = 3.78 min (system 5); LC/MS MS: m/z = 379
(MH+).
Example 4.55: [δ-Chloro-β-ζβ-methyl-pyridin-S-ylaminoj-pyridin-S-ylJ-ft-vinyl-piperidin- 1 -yl)- methanone
TLC: Rf = 0.78 (DCM/MeOH 95:5), HPLC: tR = 2.70 min (system 4); LC/MS MS: m/z = 357
(MH+).
Example 4.56: [δ-Chloro-6-(6-methvl-Dvridin-3-vlamino)-pvridin-3-vl]-(((Z)-2-propenvl)- piperidin-1 -yl]-methanone
TLC: Rf = 0.66 (DCM/MeOH 95:5), HPLC: tR = 2.88 min (system 4); LC/MS MS: m/z = 371
(MH+).
Example 4.57: fδ-Chloro-6-(6-methvl-pvridin-3-ylamino)-pyridin-3-yl]-f3-ethylidene-piperidin-
1-yl]-methanone
TLC: R, = 0.89 (DCM/MeOH 5:1), HPLC: tR = 2.85 min (system 4); LC/MS MS: m/z = 357
(MH+).
The starting material was prepared as described hereafter:
i) 3-Ethylidene-piperidine hydrochloride
To a solution of potassium-tert-butoxide (3.10 g, 27.6 mmol, 1.1 eq) in THF (30 mL) at rt was added sequentially ethyltriphenylphosphoniumbromide (11.0 g, 29.6 mmol, 1.18 eq) followed by a solution of 1-(tert-Butoxycarbonyl)-3-piperidone (5.0 g, 25.1 mmol) in THF (20 mL). After stirring the resulting suspension for 24 h at rt, water was added and the aqueous phase was extracted with DCM. The organic phases were combined, dried over sodium sulfate and the solvent removed on vacuo. After purification by flash chromatography, 3-ethylidene- piperidine-1-carboxylic acid tert-butyl ester (5.5 g, 100%) was obtained as a 1 :2 E/Z isomeric mixture. Deprotection of the Boc-group was effected by stirring 3-ethylidene-piperidine-1- carboxylic acid tert-butyl ester (5.5 g, 26 mmol) in HCI/dioxane (4M, 15 mL) for 1 h at rt. The white precipitate was filtered off, washed twice with diethyl ether and dried on vacuo to afford the desired product as beige crystals (2.99 g, 78%). LC/MS MS: m/z = 111 (MH+).
Example 4.58: [δ-Chloro-β-fβ-methvl-ovridin-S-vlaminol-pvridin-S-vll-β-propylidene-piperidin-
1-yl]-methanone
TLC: Rf = 0.16 (DCM/MeOH 95:5), HPLC: tR = 2.85 min (system 4); LC/MS MS: m/z = 371
(MH+).
3-Propylidene-piperidine hydrochloride was prepared in an overall yield of 71% starting from propyltriphenylphosphoniumbromide and 1-(tert-Butoxycarbonyl)-3-piperidone in analogy to the procedure given in Example 4.57 i. LC/MS MS: m/z = 126 (MH+).
Example 4.59: f5-Chlorθ'6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vlJ-(2-ethoxymethyl- piperidin-1 -yl)-methanone
TLC: Rf = 0.66 (DCM/MeOH 95:5), HPLC: tR = 2.88 min (system 4); LC/MS MS: m/z = 371
(MH+).
Example 4.60: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vlh(2-thoxvmethyl- piperidin-1-yl)-methanone
TLC: R, = 0.26 (DCM/MeOH 95:5), HPLC: fe = 2.55 min (system 4); LC/MS MS: m/z = 389
(MH+).
Example 4.61: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vlhf2-(2-hvdroxv-ethvl)- piperidin- 1 -yl]-methanone
TLC: R, = 0.23 (DCM/MeOH 95:5), HPLC: fe = 2.72 min (system 4); LC/MS MS: m/z = 375
(MH+).
Example 4.62: !5-Chloro-6-(6-methvl-pvndin-3-vlamino)-pvndin-3-vll-(5-fiuoro-2-propvl- piperidin- 1 -yl)-methanone
TLC: R, = 0.35 (EtOAc/hexanes 2:1), HPLC: tR = 1.60 min (system 5); LC/MS MS: m/z = 391
(MH+).
The starting material was prepared as described hereafter:
i) 5-Fluoro-2-propyl pyridine To a suspension of n-propylmagnesium chloride (13 mL, 1.0 M in diethyl ether) and zinc chloride (17 mL, 0.5 M in THF, 2.5 eq) was added 1-methyl-2-pyrrolidinone (10 mL), 2- bromo-5-fluorpyridine (600 mg, 3.41 mmol) and bis(th-tert.-butylphosphine)palladium (174 mg, 0.34 mmol, 0.1 eq). After stirring at 80 0C for 3 h the mixture was cooled to 00C, water was added resulting solution extracted with EtOAc twice. The organic phases were combined, dried over sodium sulfate and the solvent removed on vacuo. After purification by flash chromatography, 5-fluoro-2-propyl pyridine (182 mg, 30%) was obtained. LC/MS MS: m/z = 140 (MH+).
ii) 5-Fluoro-2-propyl-piperidine hydrochloride
5-Fluoro-2-propyl pyridine (182 mg, 1.04 mmol) was hydrogenated in a mixture of MeOH (10 mL) and concentrated aqueous hydrochloric acid (0.13 mL) in the presence of Nishimura catalyst (50 mg) at 4 bar for 3.5 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM. The organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford a mixture of 5-fluoro-2-propyl-piperidine hydrochloride and 2-propyl-piperidine hydrochloride as light red solid (95%) which was used in the next step without further purification.
Example 4.63: [5-Chloro-6-(6-methvl-pvridin-3~vlamino)-pvridin-3-vlJ-[2-(1.2-difluoro-propyl)- piperidin-1 -yl]-methanone and Example 4.64: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)- pyridin-3-yl]-[2-(2-fluoro-propyl)-piperidin-1-yl]-methanone
Both compounds were isolated after preparative TLC separation of the corresponding mixture.
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-[2-(1 , 2-difluoro-propyl)-piperidin- 1 -yl]- methanone: TLC: Rf = 0.39 (EtOAc/hexanes 5:1 ), HPLC: tR = 1.37 min (system 5); LC/MS
MS: m/z = 391 (MH+).
[δ-Chloro-β-fβ-methyl-pyridinS-ylaminoj-pyridin-S-ylJ-p-fi-fluoro-propylj-piperidin-i-yl]- methanone: TLC: R( = 0.40 (EtOAc/hexanes 5:1 ), HPLC: tR = 1.22 min (system 5); LC/MS
MS: m/z = 409 (MH+).
The starting material was prepared as described hereafter: i) 2-(1 ,2-Difluoro-propenyl)-pyridine
To a solution of 1-pyridin-2-yl-propan-2-one (3.75 g, 27.7 mmol) in DCM (20 ml_) at 0°C was was DAST (10.1 ml_, 69 mmol, 2.50 eq). After stirring the solution for 15 h (O°C->rt) it was diluted by DCM and subsequently quenched by slow addition of ice water. Resulting solution was extracted twice with DCM. The organic phases were combined, dried over sodium sulfate and the solvent removed on vacuo. After purification by flash chromatography 2-(1,2- difluoro-propenyl)-pyridine (616 mg, 14%) was obtained as beige oil. LC/MS MS: m/z = 156 (MH+).
ii) 2-(1,2-Difluoro-propyl)-piperidine hydrochloride, 2-(1 -fluoro-propyl)-piperidine hydrochloride and 2-propyl-piperidine hydrochloride
2-(1,2-Difluoro-propenyl)-pyridine (820 mg, 4.28 mmol) was hydrogenated in a mixture of MeOH (25 ml_) and concentrated aqueous hydrochloric acid (0.46 ml_) in the presence of Nishimura catalyst (100 mg) at atmospheric pressure for 24 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM. The organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford a mixture of 2-(1 ,2-difluoro-propyl)- piperidine hydrochloride, 2-(1-fluoro-propyl)-piperidine hydrochloride and 2-propyl-piperidine hydrochloride as light red solid (100%) which was used in the next step without further purification.
Example 4.65: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-ethyl-[1,3]o xazepan-3-yl) -methanone
TLC: R, = 0.21 (DCM/MeOH 95:5), HPLC: tR = 2.66 min (system 4); LC/MS MS: m/z = 375
(MH+).
Example 4.66: \5-Chloro-&(6-methyl-pyridm' -3-ylamino)-pyridin-3-yl]-(2-propyl-\'l,3]OY.azepan-
3-yl)-methanone
TLC: R, = 0.2 (DCM/MeOH 95:5), HPLC: tR = 2.82 min (system 4); LC/MS MS: m/z = 389
(MH+).
Example 4.67: f5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-ylhf2-(1-ethyl-propyl)-
[1 ,3]oxazepan-3-yl]-methanone TLC: R, = 0.17 (DCM/MeOH 95:5), HPLC: tR = 3.10 min (system 4); LC/MS MS: m/z = 417
(MH+).
Example 4.68: r5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vl]-(2-propyl-[1,3loxazinan-
3-yl)-methanone
TLC: R, = 0.11 (DCM/MeOH 95:5), HPLC: tR = 2.55 min (system 4); LC/MS MS: m/z = 375
(MH+).
Example 4.69: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vl]-f2-(1-ethvl-propyl)-
[1, 3]oxazinan-3-yl]-methanone
TLC: Rf = 0.18 (DCM/MeOH 95:5), HPLC: tR = 2.89 min (system 4); LC/MS MS: m/z = 403
(MH+).
Example 4.70: (2-Butyl-[1,3]oxazinan-3-yl)-[5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3- yl]-methanone
TLC: R, = 0.12 (DCM/MeOH 95:5), HPLC: tR = 2.87 min (system 4); LC/MS MS: m/z = 389
(MH+).
Example 4.71: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pyridin-3-vlJ-[2-(2-methoxv-ethyl)- piperidin-1-yl]-methanone
TLC: R, = 0.15 (DCM/MeOH 95:5), HPLC: tR = 2.60 min (system 4); LC/MS MS: m/z = 389
(MH+).
Example 4.72: r5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pvridin-3-yiπ2-phenyl-pyrrolidin-1- yl)-methanone
TLC: Rf = 0.66 (DCM/MeOH 9:1 ), HPLC: tR = 3.07 min (system 3); LC/MS MS: m/z = 393
(MH+).
Example 4.73: \b-Ch\oro-6AG-methy\-pyr\dm' -3-y\am\no)-pyr\din-3-y\]A2-pyndin-2-y\-pynol\dm' -
1-yl)-methanone
TLC: R, = 0.65 (DCM/MeOH 9:1 ), HPLC: tR = 2.48 min (system 3); LC/MS MS: m/z = 394
(MH+).
Example 4.74: [δ-Chloro-β-fβ-methvl-pyridin-S-ylaminoi-pyridin-S-ylHfRl^-ethoxy-pyrrolidin-
1-yl)-methanone
TLC: R, = 0.44 (DCM/MeOH 9:1 ), HPLC: tR = 2.09 min (system 3); LC/MS MS: m/z = 361
(MH+).
Example 4.75: [5-Chloro-6-(6-methvl-pyridin-3-ylamino)-pvridin-3-yl1-[2-(5-methyl-thiophen-2- yl)-pyrrolidin- 1 -yl]-methanone
TLC: R, = 0.5 (DCM/MeOH 9:1 ), HPLC: tR = 3.15 min (system 3); LC/MS MS: m/z = 413
(MH+). Example 4.76: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-ylJ-(2-propyl-azepan-1-yl)- methanone
TLC: Rf = 0.52 (DCM/MeOH 95:5), HPLC: tR = 3.21 min (system 3); LC/MS MS: m/z = 387
(MH+).
Example 4.77: fδ-Chloro-e-fe-methvl-pyridin-S-ylaminoj-pyridin-S-ylJ-O-propyl-morpholin-^ yl)-methanone
TLC: R, = 0.18 (DCM/MeOH 95:5), HPLC: tR = 2.53 min (system 4); LC/MS MS: m/z = 375
(MH+).
Example 5.1 : Azepan-i-vl-fδ-chloro-β-tf-chloro-phenylaminoϊ-pyridin-S-yll-methanone To a solution of 5-Chloro-6-(4-chloro-phenylamino)-nicotinic acid (72 mg, 0.25 mmol) and DIPEA (67 μL, 0.38 mmol) in 1 ,2-dimethoxyethane (1.2 mL) is added HATU (97 mg, 0.25 mmol) in one portion. The reaction mixture is stirred for 30 min at RT. Then, hexamethylene imine (24 μL, 0.2 mmol) is injected and stirring is continued for further 6h. The reaction mixture is evaporated to dryness and the residue is purified by preparative HPLC (YMC Pack Pro C18 5 μm, 150 x 30 mm; AcN-H2O-0.1% TFA gradient 10% -> 100% AcN; flow: 20 mL min"1). The fractions containing the product are combined and acetonitrile is evaporated. The remaining aqueous solution is made alkaline by addition of solid NaHCO3 and extracted with ethyl acetate. The organic layer is separated, washed with brine, dried over Na2SO4, and evaporated to dryness to afford the title compound as a colorless powder (75 mg, 81%), HPLC: tR = 7.0 min (system 1); ESI+ MS: m/z = 364.0, 366.0 (MH+).
The starting material can be prepared as described hereafter:
5-Chloro-6-(4-chloro-phenylamino)-nicotinic acid
A solution of δ.e-dichloronicotinic acid (0.5 g, 2.55 mmol) and 4-chloroaniline (293 mg, 2.30 mmol) in glacial acetic acid (5 mL) is microwave heated to 150 0C for 75 min. To the clear solution is added ethyl acetate (10 mL). After a short time the product starts to crystallize. The precipitate is filtered off, washed with ethyl acetate, and vacuum dried at room temperature to afford the desired product as a colorless powder (470 mg, 65%).
Following the same procedure, the following compounds can be prepared: Example 5.2: rac-[5-Chloro-6-(4-chloro-phenylamino)-pyridin-3-yl]-(3-methyl-piperidin-1 -yl)- methanone
Colorless syrup, HPLC: tR = 7.2 min (system 1); ESI+ MS: m/z = 364.0, 366.0 (MH+). Using either S-3-methylpiperidine or ft-3-methylpiperidine as starting material the pure enantiomers could be prepared:
Example 5.2a: t5-Chloro-6-(4-chloro-phenylamino)-pyridin-3-vl]-(S-3-methyl-piperidin-1-yl)- methanone Brown gum, HPLC: tR = 7.4 min (system 1); ESI+ MS: m/z = 364.0, 366.0 (MH+).
Example 5.2b: f5-Chloro-6-(4-chloro-phenylamino)-pyridin-3-yll-(R-3-methyl-piperidin-1-yl)- methanone Brown gum, HPLC: tR = 7.3 min (system 1); ESI+ MS: m/z = 364.0, 366.0 (MH+).
Example 5.3: AzeDan-1-vl-[2-(4-chloro-phenvlamino)-pvrimidin-5-yll-methanone Colorless crystals, HPLC: tR = 6.4 min (system 1); ESI+ MS: m/z = 331.5 (MH+).
Example 5.4: [2-(4-Chloro-phenvlamino)-pyrimidin-5-yl]-piperidin-1-vl-methanone Colorless crystals, HPLC: tR = 6.2 min (system 1 ); ESI+ MS: m/z = 317.6 (MH+).
Example 5.5: rac-f2-(4-Chloro-phenylamino)-pynmidin-5-vll-(3-methyl-piperidin-1-yl)- methanone
Colorless crystals, HPLC: tR = 6.5 min (system 1 ); ESI+ MS: m/z = 331.6 (MH+).
Example 6.1 : Azepan-1-vl-f6-(4-chloro-phenvlamino)-5-methoxv-pyridin-3-yll-methanone To a solution of azepan-i-yl^e-chloro-S-methoxy-pyridin-S-yO-methanone (198 mg, 0.70 mmol) and 4-chloroaniiine (270 mg, 2.11 mmol) in toluene (5 mL) is added finely ground anhydrous K2CO3 (491 mg, 3.52 mmol). To the suspension obtained is added a still warm solution prepared by dissolving palladium(ll) acetate (10 mg, 0.04 mmol) and BINAP (27 mg, 0.04 mmol) in toluene (1 mL) with stirring for 20 min at 90°C. The reaction mixture is stirred under argon for 21 h at 80 0C. After cooling ethyl acetate (40 mL) is added and the solution is extracted with water (3x 15 mL). The organic layer is isolated, dried over Na2SO4 and evaporated to dryness to give a dark green oil. The crude product is purified by flash chromatography (24 g silica gel, MeOH-MTBE gradient 2% -> 15% MeOH, flow 20 mL min1). Recrytallization from Et2O gives the desired compound as beige crystals, TLC: Rt = 0.14 (MTBE), HPLC: tR = 7.0 min (system 1 ); ESI+ MS: m/z = 360.1 (MH+).
The starting material can be prepared as described hereafter: i) β-chloro-δ-methoxynicotinic acid
To a solution of methyl 6-chloro-5-hydroxynicotinate (0.95 g, 5.07 mmol, prepared according to WO 00/51614) in DMSO (9.5 mL) is added powdered 85% KOH (0.67 g, 10.1 mmol) followed by slow injection of methyl iodide (0.35 mL, 5.57 mmol). The reaction mixture is stirred over night at RT. To achieve complete hydrolysis of the intermediate ester water (1 mL) is added and stirring is continued for further 30 min. The solution is diluted with 1M HCI (100 mL) and extracted with ethyl acetate (1x 100 mL, 3x 50 mL). The combined organic extracts are dried over Na2SO4 and evaporated to give a yellow solid residue. Trituration with H2O (20 mL) followed by drying in vacuo at 65°C affords the title compound as beige powder (846 mg, 89%).
H) Azepan-1-yl-(6-chloro-5-methoxy-pyhdin-3-yl)-methanone
A mixture of e-chloro-S-methoxynicotinic acid (272 mg, 1.45 mmol) and thionyl chloride (3.2 mL) is stirred for 30 min at 75 °C. The clear solution is evaporated to dryness and the residue is redissolved in DCM (4 mL) under argon. After the addition of triethylamin (2 mL, 14.5 mmol) and hexamethyleneamine (0.2 mL, 1.74 mmol) the yellow turbid reaction mixture is stirred for 1h at RT. Then MTBE (30 mL) is added and the solution is extracted with H2O (3x 10 mL), dried over Na2SO4 and evaporated to give the title compound as a yellow oil (407 mg, 100%). The material can be used in the next step without further purification.
Following the same procedure, the following compounds can be obtained:
Example 6.2: Azepan-1 -yl-[5-methoxy-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]- methanone]
Yellow lyophilisate, TLC: R, = 0.16 (MTBE-MeOH 9:1 ), HPLC: fe = 4.5 min (system 1); ESI+
MS: m/z = 341.1 (MH+).
Example 6.3: [6-(4-Chloro-phenylamino)-5-methoxy-pyridin-3-yl]-piperidin- 1 -yl-methanone Yellowish crystals, TLC: R, = 0.13 (MTBE), HPLC: tR = 6.9 min (system 1 ); ESI+ MS: m/z = 346.1 (MH+). Example 6.4: [δ-Methoxy-β-fδ-methyl-pyridinS-ylaminoj-pyridin-S-ylJ-piperidin- 1 -yl- methanone
Yellowish lyophilisate, TLC: Rf = 0.15 (MTBE-MeOH 9:1), HPLC: tR = 4.0 min (system 1);
ESI+ MS: m/z = 327.1 (MH+).
Example 6.5: Azepan- 1 -yl-[6-(4-chloro-phenylamino)'5-ethoxy-pyridin-3-yl]-methanone Colorless lyophilisate, TLC: Rf = 0.29 (MTBE), HPLC: tR = 7.4 min (system 1 ); ESI+ MS: m/z = 374.1 (MH+).
Example 6.6: Azepan- 1 -yl-[5-ethoxy-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-methanone Colorless lyophilisate, TLC: R, = 0.25 (MTBE-MeOH 9:1), HPLC: tp = 4.6 min (system 1); ESI+ MS: m/z = 355.2 (MH+).
Example 6.7: [5-Ethoxy-6-(6-methyl-pyndin-3-ylamino)-pyridin-3-yl]-piperidin- 1 -yl-methanone Colorless lyophilisate, TLC: R( = 0.21 (MTBE-MeOH 9:1), HPLC: tR = 4.4 min (system 1 ); ESI+ MS: m/z = 341.2 (MH+).
Example 7.1 : fS-Chloro-β-fβ-chloro-pyridinS-vlaminoi-pyridin-S-vlJ-fS-methvl-piperidin-i-vl)- methanone
A solution of 5-[3-Chloro-5-(3-methyl-piperidine-1-carbonyl)-pyridin-2-ylamino]-1H-pyridin-2- one (88 mg, 0.25 mmol) and DMAP (5 mg, 0.04 mmol) in phosphoryl chloride (2.75 mL) is refluxed under argon for 90 h. After cooling the suspension obtained is evaporated and taken up in DCM (40 mL) - 20% KHCO3 solution (40 mL). The organic layer is washed (1x 20% KHCO3, 40 mL; 2x H2O, 20 mL), dried over Na2SO4 and evaporated to give a reddish turbid syrup. The crude material is purified by flash chromatography (25 g silica gel, eluent MTBE1 flow 20 mL min") to afford a bluish foam (37 mg, 40%), TLC: R, = 0.39 (MTBE), HPLC: tR = 6.4 min (system 1 ); ESI+ MS: m/z = 365.0 (MH+).
The starting material can be prepared as described hereafter:
5-l3-Chloro-5-(3-methyl-piperidine-1-carbonyl)φyridin-2-ylamino]-1H-pyridin-2-one
To a solution of [5-Chloro-6-(6-methoxy-pyridin-3-ylamino)-pyridin-3-yl]-(3-methyl-piperidin-1- yl)-methanone (489 mg, 1.36 mmol, prepared from 5,6-dichloronicotinic acid, 3- methylpiperidine and 3-amino-6-methoxypyridine according to the procedure given in example 5.1) in 1 ,2-dichloroethane (30 mL) is added iodotrimethyl silane (0.47 mL, 3.39 mmol) in one portion. The reaction mixture is stirred for 6 h at 70°C under argon. After cooling the reaction is quenched with methanol (3 mL) stirred for 15 min at RT and evaporated. The residue is taken up in a mixture of DCM (40 mL) and triethyl amine (1 mL), extracted (1x H2O, 20 mL; 1x 5% NaS2O3, 20 mL, 1x H2O, 20 mL), dried over Na2SO4 and evaporated to afford greenish residue. The crude product is purified by flash chromatography (54 g silica gel, MeOH-DCM gradient 0% -> 10% MeOH, flow 40 mL min"1) to afford a beige foam (401 mg, 85%).
Example 8.1 : f6-(4-Chloro-phenvlamino)-Dvridazin-3-vll-piperidin-1-yl-methanone To a solution of θ-^-Chloro-phenylaminoJ-pyridazine-S-carboxylic acid (50 mg, 0.2 mmol) and DIPEA (53 μL, 0.3 mmol) in DMA (1 mL) is added HATU (76 mg, 0.2 mmol) in one portion. The reaction mixture is stirred for 30 min at RT. Then piperidine (16 uL, 0.16 mmol) is injected and stirring is continued for further 6 h. The solution is diluted with ethyl acetate (20 mL), extracted (2x brine, 20 mL), dried over Na2SO4 and evaporated to dryness to give an olive solid. The crude product is purified by flash chromatography (10 g silica gel, ETOAC-hexanes gradient 0% -> 80% ETOAC, flow 15 mL min"1) followed by crystallization from ether / hexanes to afford the title compound as beige powder (21 mg, 33%), HPLC: tR = 5.8 min (system 1); ESI+ MS: m/z = 317.5 (MH+).
The starting material can be prepared as described hereafter: β-f^Chloro-phenylaminoj-pyridazine-d-carboxylic acid
A solution of β-chloropyridazine-S-carboxylic acid (0.5 g, 3.15 mmol, [5096-73-1]) and 4- chloroaniline (805 mg, 6.31 mmol) in 1 ,2-dimethoxyethane (5 mL) is microwave heated for 20 min at 100 0C. After cooling the reaction mixture is diluted with ethyl acetate (10 mL) and stirred for 5 min. The brown precipitate is filtered off and triturated with cold water (30 mL). The light brown suspension is filtered and washed with water. After vacuum dry at 45°C the product is obtained as a beige powder (250 mg, 32%).
Following the same procedure, the following compounds can be obtained:
Example 8.2: rac-tβ-^-Chloro-phenylaminoj-pyridazin^-ylJ-β-methyl-piperidin- 1 -yl)- methanone
Gray powder, HPLC: tR = 6.1 min (system 1 ); ESI+ MS: m/z = 331.6 (MH+). Example 8.3: [6-(4-Chloro-phenylamino)-pyridazin-3-yl]-(3, 3-dimethyl-piperidin-1-yl)- methanone
Beige powder, HPLC: tR = 6.3 min (system 1); ESI+ MS: m/z = 345.6 (MH+).
Example 8.4: [6-(4-Chloro-phenvlamino)-pvridazin-3-yll-(3,4-dihydro-1H-isoquinolin-2-yl)- methanone
Beige powder, HPLC: tR = 6.4 min (system 1); ESI+ MS: m/z = 365.6 (MH+).
Example 8.5: [6-(4-Chloro-phenylamino)-pyhdazin-3-yl]-(4-methyl-piperidin- 1 -yl)-methanone Gray powder, HPLC: tR = 6.1 min (system 1); ESI+ MS: m/z = 331.6 (MH+).
Example 9.1: [5-Methyl-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-piperidin-1-yl-methanone
To a solution of 5-methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid (130 mg, 0.534 mmol) in DMF (15 mL), HOBt (106 mg, 0.74 mmol) and 4-methylmorpholine (180 μL, 1.61 mmol) were added. After 10 min of stirring, EDC (146 mg, 0.74 mmol) and piperidine (74.6 μL, 0.74 mmol) were added and the resulting mixture was stirred at 500C for 16 hours. The solvent was removed in vacuo and EtOAc was added. The organic phase was washed with a saturated solution of NaHCO3, dried over sodium sulfate and concentrated in vacuo to afford a brown resin. The crude product was purified by flash chromatography over silica gel using EtOAc as solvent to afford [5-methyl-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-piperidin-1- yl-methanone (30 mg, 18%) as a yellow resin.
The starting material was prepared as described hereafter:
i) N-tert-butyldimethylsilyl isopropyl formimidate
At -400C, to a suspension of isopropyl formimidate hydrochloride (12.9 g, 105 mmol) in DCM (150 mL), triethylamine (32.3 mL, 231 mmol) was added in once. Then, a solution of tert- butyldimethylsilyl triflate (24.6 mL, 105 mmol) in DCM (100 mL) was added drop-wise with keeping the temperature below -40°C. At the end of the addition, 25 mL of hexanes was added at once and the mixture was then allowed to reach RT. The precipitate was filtered off and washed with hexanes and DCM. The filtrate was concentrated in vacuo to afford a yellow paste. Et2O was added and the residual triethylammonium triflate was removed by decantation. The etheral phase was concentrated in vacuo to afford N-tert-butyldimethylsilyl isopropyl formimidate as a clear oil (15.53 g, 73.5%) which will be used without further purification.
ii) 6-Hydroxy-5-methyl-nicotinic acid ethyl ester
At RT, a solution of propionyl chloride (1.55 ml_, 17.4 mmol) in 3.5 ml_ of toluene was added drop-wise to a solution of N-tert-butyldimethylsilyl isopropyl formimidate (3.51 g, 17.4 mmol) and triethylamine (12.2 ml_, 87 mmol) in 10 ml_ of toluene. The resulting mixture was stirred at RT for 2 hours and then 10 mL of hexanes was added. The precipitate was removed by filtration and washed with hexanes (3 x 5 mL). The solution was concentrated in vacuo to afford a clear oil. This oil was solubilised in toluene (15 mL) and ethyl propiolate (1.2 mL, 11.6 mmol) was added. The resulting mixture was stirred at 85°C for 70 hours. The mixture was concentrated in vacuo and then diluted with HCI 2N. The aqueous phase was extracted with DCM. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford a crude yellow paste (3.5 g). The crude product was purified by flash chromatography over silica gel using Hexanes/EtOAc (75/25 to 0/100) as solvent gradient to afford 6-hydroxy-5-methyl-nicotinic acid ethyl ester (1.65 g, 78.5%) as a yellow powder. (ES- MS: m/z 182.1 [M+H]+, fe 3.28 min (system 2)).
iii) 6-Chloro-5-methyl-nicotinic acid ethyl ester
A mixture of 6-hydroxy-5-methyl-nicotinic acid ethyl ester (1.65 g, 9.11 mmol) in POCI3 (2.55 mL, 27.3 mmol) was stirred at 1200C for 1.5 hour. The mixture was cooled down and poured into ice. The resulting precipitate was filtered off, washed with water and then solubilised in DCM. The organic phase was dried over sodium sulfate and then concentrated in vacuo to afford 6-chloro-5-methyl-nicotinic acid ethyl ester (1.55 g, 85%) as a dark brown solid. (ES- MS: m/z 241.1/243.1 [M+CH3CN+H]\ tR 5.12 min (system 2)).
iv) 5-Methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid ethyl ester A mixture of 6-chloro-5-methyl-nicotinic acid ethyl ester (750 mg, 3.76 mmol), 3-amino-6- methyl pyridine (609 mg, 5.64 mmol), Pd(OAc)2 (26 mg, 0.11 mmol), rac-BINAP (72 mg, 0.11 mmol) and potassium carbonate (2.62 g, 18.8 mmol) in degassed toluene (20 mL) was stirred, under argon, at 800C for 4 hours. EtOAc was added and the organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to afford the 5- methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid ethyl ester (1.02 g, 100%) as a black solid. (ES-MS: m/z 272.2 [M+Hf, tR 3.37 min (system 2)).
v) 5-Methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid
To a solution of 5-methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid ethyl ester (1.02 g, 3.76 mmol) in THF/MeOH (1/1, 40 ml_), NaOH 2N (3.8 ml_, 7.6 mmol) was added. The mixture was stirred at RT for 16 hours. The solvent was removed in vacuo and the crude was diluted with water. The aqueous was acidified to pH 4-5 by addition of HCI 2N. The resulting precipitate was removed by filtration and dried under high-vacuum to afford 5-methyl-6-(6- methyl-pyridin-3-ylamino)-nicotinic acid (615 mg, 67%) as a beige solid. (ES-MS: m/z 244.1 [M+H]+, tR 2.77 min (system 2)).
Example 9.2: [5-Fluoro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-piperidin-1-yl-methanone [5-Fluoro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-piperidin-1-yl-methanone was prepared following the procedure described in example 9.1. TLC: Rf = 0.14 (EtOAc/hexanes 1 :9), LC/MS: m/z = 315 (MH+).
The starting material can be prepared as described in example 9.1. v) and iv) starting from 6- Chloro-5-fluoro-nicotinic acid methyl ester.
Example 10: Example of Biological Testing.
Activity of the Example compounds of the present invention, non limiting to the other compounds of the invention but merely used by way of example, was examined by measurement of the inhibition of the glutamate induced elevation of intracellular Ca2+- concentration following similar methods than those described in L. P. Daggett et al., Neuropharm. Vol. 34, pages 871-886 (1995), P. J. Flor et al., J. Neurochem. Vol. 67, pages 58-63 (1996).
The table below represents percentages of inhibition of the glutamate induced elevation of intracellular Ca2+-concentration at a concentration of 10 μM.
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000072_0002
Figure imgf000073_0001
Figure imgf000073_0002
Figure imgf000074_0001
Figure imgf000074_0002
Example 11 : Clinical Testing
The action of mGluR modulatos, e.g. mGluR anatagonists on cognition and cognitive disorders, as described herein may be conducted in the following way.
Firstly, it has been found through imaging techniques that the compounds of the present invention are able to penetrate the brain and bind to mGluR receptors, in particular mGluR5 receptors. Secondly, it has been observed that patients taking a compound, such as an mGluR modulators as described herein have shown an increase in cognition or the like.
Clinical testing of the compounds as mentioned herein may be conducted, for example, in one of the following study designs. The skilled person will of course realise that such studies are considered as guidelines and the certain aspects of the studies may be modified and redefined depending on the circumstance and environment, for example. Clinical Design 1: Improvement Trials
Trial A: Normal Patient Population
A patient population, with a normal control is dosed once a day for a week or longer and cognition is tested. The test is designed to allow for improvement, I.e. that there is a measurable parameter increase. The patients are tested at the beginning and at the end of the dosage period and the results are compared and analysed.
Trial B: Deficit population
A patient population with a cognitive deficit is dosed once a day for a week or longer and cognition is tested. The test is designed to allow for improvement, I.e. that there is a measurable parameter increase. The patients are tested at the beginning and at the end of the dosage period and the results are compared and analysed.
Considerations for designing a trial
• When designing a trial, the skilled person will appreciate the need to protect both against floor and ceiling effects. In other words, the study designing should allow cognition to the measurably raised or lowered.
• Conditions that artificially impair cognition, are one way to test enhancement of cognition. Such conditions are, for example, sleep deprivation and pharmacological challenges.
• Placebo control is required for all trials.
• In assessing the data, evaluation of the likelihood of learning and practice effects from repeat assessments must be made. The likelihood of such effects contaminating the data to produce false positives should be taken in to account when designing the test, e.g. the tests should not be identical (e.g. commit the same list of words to memory) but designed to study the same mechanism of cognition. Other countermeasures may include single testing at the end of a trial only.

Claims

1. The use of an mGluR modulator for the treatment, prevention or delay of progression of cognitive dysfunction.
2. Use according to claim 1 , wherein the modulator is an mGluR5 modulator.
3. Use according to claim 1 or claim 2, wherein the modulator is an mGluR antagonist.
4. Use according to claim 2 or claim 3, wherein the modulator is an mGluR5 antagonist.
5. Use according to any preceding claim, wherein the modulator is a compound of the formula (I)
Figure imgf000076_0001
wherein
R1 represents optionally substituted alkyl or optionally substituted benzyl; and
R2 represents hydrogen (H), optionally substituted alkyl or optionally substituted benzyl; or
R1 and R2 form together with the nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
R3 represents halogen, alkyl, alkoxy, alkylamino or dialkylamino;
R4 represents hydroxy (OH), halogen, alkyl or alkoxy;
Q represents CH, CR4 or N;
V represents CH, CR4 or N; W represents CH, CR4 or N; X represents CH or N;
Y represents CH, CR3 or N;
Z represents CH2, NH or O; and provided that Q, V and W are not N at the same time; in free base or acid addition salt form.
6. Use according to any of claims 1 to 4, wherein the modulator is a compound of the formula (II), wherein a compound of the formula (II) is a compound of formula (I) in which at least one of Q, V and W is N, in free base or acid addition salt form.
7. Use according to any of claims 1 to 4, wherein the modulator is a compound of the formula (IV) or the formula (V):
Figure imgf000077_0001
wherein m is 0 or 1 , n is 0 or 1 and
A is hydroxy
X is hydrogen and
Y is hydrogen, or
A forms a single bond with X or with Y;
R0 is hydrogen, (C1-4)alkyl, (C1^aIkOXy, trifluoromethyl, halogen, cyano, nitro, -COOR1 wherein R1 is (C^alkyl or -COR2 wherein R2 is hydrogen or (C1-4)alkyl, and
R is -COR3, -COOR3, -CONR4R5Or -SO2R6, wherein R3 is (C1-4)alkyl, (C3.7)cycloalkyl or optionally substituted phenyl, 2-pyridyl or 2-thienyl; R4 and R5, independently, are hydrogen or
Figure imgf000077_0002
(C3-7 )cycloalkyl or optionally substituted phenyl,
R' is hydrogen or (d^)alkyl and
R" is hydrogen or (d.4)alkyl, or
R' and R" together form a group -CH2-(CH2)m- wherein m is O, 1 or 2, in which case one of n and m is different from 0, with the proviso that R0 is different from hydrogen, trifluoromethyl and methoxy when n is 0,
A is hydroxy, X and Y are both hydrogen, R is COOEt and R' and R" together form a group ■
(CHa)2-. OR
Figure imgf000078_0001
wherein
R1 represents hydrogen or alkyl;
R2 represents an unsubstituted or substituted heterocycle or
R2 represents an unsubstituted or substituted aryl;
R3 represents alkyl or halogen;
X represents a single bond or an alkandiyl-group, optionally interrupted by one or more oxygen atoms or carbonyl groups or carbonyloxy groups; in free base or acid addition salt form.
8. Use according to any preceding claim, wherein the cognitive dysfunction comprises a disorder selected from deficits and abnormalities in attention and vigilance, executive functions and memory (for instance working memory and episodic memory), sleep related breathing disorders (SRBD), behavioral impairments, information processing deficits and age-related disorders.
9. Use according to any preceding claim, wherein the cognitive dysfunction is associated with a disorder selected from sleep related breathing disorders (SRBDs), behavioral impairments, attention-deficit hyperactivity disorder (ADHD), childhood ADHD, adult ADHD, excess daytime somnolence, sleep apnea, shift-worker's sleep-wake cycle disruption, traumatic brain injury, neurodegenerative disorders with associated memory, cognitive problems (such as Alzheimer's disease, Lewy body dementia, senile dementia, vascular dementia, Parkinson's disease), chronic fatigue syndrome, fatigue associated with sleep deprivation or prolonged wakefulness, age-related decline in memory and cognitive function (such as mild cognitive impairment), mood disorders (such as depression), anxiety, schizophrenia and daytime sleepiness associated with narcolepsy.
10. A method for the treatment, prevention or delay of progression of cognitive dysfunction in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of an mGluR modulator.
11. A method according to claim 10, wherein the mGluR modulator is as defined in any of claims 2 to 7.
12. A method according to claim 10 or claim 11 , wherein the mGluR modulator is an mGluR5 modulator.
13. A method according to claim 12, wherein the mGluR modulator is an mGluR5 antagonist.
14. A method according to any of claims 10 to 13, wherein the cognitive dysfunction is as defined in claim 8 or claim 9.
15. A pharmaceutical composition comprising an mGluR modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.
16. A composition according to claim 15, wherein the mGluR modulator is as defined in any of claims 2 to 7.
17. A composition according to claim 15 or claim 16, wherein the mGluR modulator is an mGluR5 modulator
18. A composition according to claim 16 or claim 17, wherein the mGluR modulator is an mGluR5 antagonist.
19. A kit comprising an mGluR modulator and instructions for using the modulator in the treatment, prevention or delay of progression of cognitive dysfunction. PAGE INTENTIONALLY LEFT BLANK
PCT/EP2007/007873 2006-09-11 2007-09-10 Nicotinic acid derivatives as modulators of metabotropic glutanate receptors WO2008031550A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US12/440,284 US20100041641A1 (en) 2006-09-11 2007-09-10 Uses of metabotropic glutamate receptors
EP07818088A EP2069305A2 (en) 2006-09-11 2007-09-10 Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
MX2009002684A MX2009002684A (en) 2006-09-11 2007-09-10 New uses of metabotropic glutamate receptors.
BRPI0716527-7A2A BRPI0716527A2 (en) 2006-09-11 2007-09-10 uses of metabotrophic glutamate receptors
AU2007296964A AU2007296964B2 (en) 2006-09-11 2007-09-10 Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
JP2009527065A JP2010502664A (en) 2006-09-11 2007-09-10 Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
CA002663113A CA2663113A1 (en) 2006-09-11 2007-09-10 Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
US13/569,734 US20120309742A1 (en) 2006-09-11 2012-08-08 Use of metabotropic glutamate receptors
US14/200,085 US20140187600A1 (en) 2006-09-11 2014-03-07 Use of metabotropic glutamate receptors

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP06120424.4 2006-09-11
EP06120424 2006-09-11
US86880506P 2006-12-06 2006-12-06
US86881406P 2006-12-06 2006-12-06
US60/868,805 2006-12-06
US60/868,814 2006-12-06
US88525507P 2007-01-17 2007-01-17
US60/885,255 2007-01-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/440,284 A-371-Of-International US20100041641A1 (en) 2006-09-11 2007-09-10 Uses of metabotropic glutamate receptors
US13/569,734 Continuation US20120309742A1 (en) 2006-09-11 2012-08-08 Use of metabotropic glutamate receptors

Publications (2)

Publication Number Publication Date
WO2008031550A2 true WO2008031550A2 (en) 2008-03-20
WO2008031550A3 WO2008031550A3 (en) 2008-08-21

Family

ID=39184158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/007873 WO2008031550A2 (en) 2006-09-11 2007-09-10 Nicotinic acid derivatives as modulators of metabotropic glutanate receptors

Country Status (9)

Country Link
US (3) US20100041641A1 (en)
EP (2) EP2069305A2 (en)
JP (2) JP2010502664A (en)
KR (1) KR20090061041A (en)
AU (1) AU2007296964B2 (en)
CA (1) CA2663113A1 (en)
MX (1) MX2009002684A (en)
RU (1) RU2014104384A (en)
WO (1) WO2008031550A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009047296A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment op parkinson's disease
WO2010000763A2 (en) * 2008-06-30 2010-01-07 Novartis Ag Combination products
EP2482657A1 (en) * 2009-09-21 2012-08-08 Vanderbilt University O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
US20160075696A1 (en) * 2014-09-11 2016-03-17 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9611251B2 (en) 2013-03-13 2017-04-04 Janssen Pharmaceutica Nv Substituted piperidine compounds and their use as orexin receptor modulators
US9611277B2 (en) 2013-03-13 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9637496B2 (en) 2013-03-13 2017-05-02 Janssen Pharmaceutica Nv Substituted 7-azabicycles and their use as orexin receptor modulators

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012254934B2 (en) * 2007-10-12 2013-10-17 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of Parkinson's disease
ES2547269T3 (en) * 2008-08-12 2015-10-05 Novartis Ag Procedures for the preparation of 4-oxo-octahydro-indole-1-carboxylic acid methyl ester and derivatives thereof
US20130274294A1 (en) * 2010-12-20 2013-10-17 David Carcache 4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073283A1 (en) * 1999-06-02 2000-12-07 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
JP2002538121A (en) 1999-03-03 2002-11-12 メルク エンド カムパニー インコーポレーテッド Inhibitors of prenyl protein transferase
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (en) 2002-06-20 2002-06-20 Astrazeneca Ab New use
KR20050033070A (en) 2002-08-09 2005-04-08 아스트라제네카 에이비이 [1,2,4]oxadiazoles as modulators of metabotropic glutamate receptor-5
JP2006519251A (en) * 2003-03-04 2006-08-24 アデックス ファーマシューティカルズ ソシエテ アノニム Novel aminopyridine derivatives as mGluR5 antagonists
WO2005044267A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
CN1871001A (en) 2003-10-31 2006-11-29 阿斯利康(瑞典)有限公司 Alkynes III
EP1677789A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes i
US20070149547A1 (en) 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
DE102004020908A1 (en) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituted 5,6,7,8-tetrahydropyrido [4,3-d] pyrimidin-2-yl and 5,6,7,8-tetrahydroquinazolin-2-yl compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
TW200801005A (en) 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
AR058554A1 (en) * 2005-12-20 2008-02-13 Novartis Ag HITEROCICLIC COMPOUNDS NITROGENATED OF 6 SUBSTITUTED MEMBERS, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY MGLUR5.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073283A1 (en) * 1999-06-02 2000-12-07 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009047296A3 (en) * 2007-10-12 2009-08-20 Novartis Ag Metabotropic glutamate receptor modulators for the treatment op parkinson's disease
WO2009047296A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment op parkinson's disease
RU2496494C2 (en) * 2008-06-30 2013-10-27 Новартис Аг COMBINATIONS CONTAINING mGluR MODULATORS FOR TREATING PARKINSON'S DISEASE
WO2010000763A2 (en) * 2008-06-30 2010-01-07 Novartis Ag Combination products
WO2010000763A3 (en) * 2008-06-30 2010-02-25 Novartis Ag Combinations comprising mglur modulators for the treatment of parkinson's disease
US8703809B2 (en) 2008-06-30 2014-04-22 Novartis Ag Combination products
CN103212078A (en) * 2008-06-30 2013-07-24 诺瓦提斯公司 Combinations comprising mglur modulators for the treatment of parkinson's disease
EP2482657A1 (en) * 2009-09-21 2012-08-08 Vanderbilt University O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
EP2482657A4 (en) * 2009-09-21 2013-05-15 Univ Vanderbilt O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
US9611251B2 (en) 2013-03-13 2017-04-04 Janssen Pharmaceutica Nv Substituted piperidine compounds and their use as orexin receptor modulators
US9611277B2 (en) 2013-03-13 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9637496B2 (en) 2013-03-13 2017-05-02 Janssen Pharmaceutica Nv Substituted 7-azabicycles and their use as orexin receptor modulators
US9695183B2 (en) 2013-03-13 2017-07-04 Janssen Pharmaceutica Nv Substituted 7-azabicycles and their use as orexin receptor modulators
US9845333B2 (en) 2013-03-13 2017-12-19 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US10183953B2 (en) 2013-03-13 2019-01-22 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US20160075696A1 (en) * 2014-09-11 2016-03-17 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9611262B2 (en) * 2014-09-11 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators

Also Published As

Publication number Publication date
JP2010502664A (en) 2010-01-28
EP2272509A1 (en) 2011-01-12
EP2069305A2 (en) 2009-06-17
KR20090061041A (en) 2009-06-15
CA2663113A1 (en) 2008-03-20
US20140187600A1 (en) 2014-07-03
AU2007296964B2 (en) 2012-05-31
RU2014104384A (en) 2015-08-20
JP2014088404A (en) 2014-05-15
US20120309742A1 (en) 2012-12-06
US20100041641A1 (en) 2010-02-18
WO2008031550A3 (en) 2008-08-21
MX2009002684A (en) 2009-06-05
AU2007296964A1 (en) 2008-03-20
JP5860865B2 (en) 2016-02-16

Similar Documents

Publication Publication Date Title
AU2007296964B2 (en) Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
EP1966144A1 (en) Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
AU2007280326B2 (en) N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof
US9567324B2 (en) Substituted nicotinamide derivatives as kinase inhibitors
CN101268073B (en) Heterocyclic compound, and production process and use thereof
TW202144345A (en) Kras mutant protein inhibitors
AU2005300736B2 (en) Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
JPH0233705B2 (en)
TW200413353A (en) Azaarene derivatives
MX2011001349A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
TW200901996A (en) Inhibitors of focal adhesion kinase
WO2007023768A1 (en) Novel pyridine derivative and pyrimidine derivative (3)
KR20140097402A (en) Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
AU2014367283B2 (en) Maleimide derivatives as modulators of WNT pathway
IE903403A1 (en) Pyrimidine-4,6-dicarboxylic acid diamides, processes for¹their preparation and the use thereof, and pharmaceuticals¹based on these compounds
TW200526641A (en) Amidopyrazole derivatives
WO2005085201A1 (en) Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein
JP2017534569A (en) PI3K, condensed quinoline compounds as mTOR inhibitors
WO2021079962A1 (en) Pharmaceutical composition for prevention and/or treatment of hearing loss
ES2838448T3 (en) Substituted dialkyl (oxide) -lambda4-sulfanilidene-nicotinamide derivatives as kinase inhibitors
CN105801584B (en) Novel aryl amide Raf kinase and its preparation method and application
JP2008133269A (en) Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780041686.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007818088

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007296964

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009527065

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2663113

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/002684

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1722/DELNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007296964

Country of ref document: AU

Date of ref document: 20070910

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097007379

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009113258

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12440284

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07818088

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0716527

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090310